{
  "dataset": "ist3",
  "total_mechanisms_analyzed": 15,
  "total_abstracts_retrieved": 147,
  "overall_support_count": 11,
  "overall_conflict_count": 8,
  "overall_neutral_count": 128,
  "mechanism_results": [
    {
      "feature_name": "Age",
      "mechanism": {
        "mechanism_type": "physiological",
        "description": "Older age is associated with reduced neuroplasticity and frailty, impacting synaptic adaptation and regenerative processes after stroke.",
        "evidence_level": "strong"
      },
      "query": "(stroke OR alteplase OR thrombolysis OR \"ischemic stroke\") AND \"Age\" AND (\"physiology\" OR \"pathogenesis\" OR \"homeostasis\") AND (\"neuroplasticity\" OR \"regenerative\" OR \"adaptation\") AND (Clinical Trial[PT] OR Review[PT] OR Meta-Analysis[PT])",
      "total_abstracts": 20,
      "support_count": 2,
      "conflict_count": 0,
      "neutral_count": 18,
      "support_percentage": 10.0,
      "conflict_percentage": 0.0,
      "support_ratio": 0.1,
      "abstracts_analyzed": [
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses human temperature regulation under heat stress and notes that intrinsic factors such as age can influence deep body temperature control, but it does not address neuroplasticity, frailty, synaptic adaptation, or regenerative processes after stroke. Therefore, it neither supports nor contradicts the specific proposed mechanism about age-related reductions in neuroplasticity affecting post-stroke recovery.",
          "key_findings": "The review examines how morphological features, intrinsic factors (including age), diseases, and injuries affect regulation of deep body temperature during heat stress, but it focuses on thermoregulation and autonomic control of heat loss rather than neural plasticity or post-stroke synaptic and regenerative changes.",
          "pmid": "35679471",
          "title": "Human temperature regulation under heat stress in health, disease, and injury.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract is a conceptual/methodological discussion about microglial state nomenclature and classification. It does not present empirical data on age-related changes in neuroplasticity, frailty, synaptic adaptation, or regenerative processes after stroke, nor does it link aging microglial states to stroke recovery outcomes.",
          "key_findings": "The paper argues that traditional dichotomous classifications of microglia (e.g., resting vs. activated, M1 vs. M2) are inadequate, and proposes a conceptual framework and nomenclature to better capture diverse microglial states across development, plasticity, aging, and disease. No specific mechanistic or outcome data on age-related neuroplasticity or post-stroke regeneration are provided.",
          "pmid": "36327895",
          "title": "Microglia states and nomenclature: A field at its crossroads.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract is a conceptual whitepaper on definitions of cognitive reserve, brain reserve, and brain maintenance. It does not present empirical data on age-related changes in neuroplasticity, frailty, synaptic adaptation, or post-stroke regenerative processes, nor does it analyze age effects on recovery after stroke.",
          "key_findings": "The workgroup establishes consensus definitions and guidelines for research on cognitive reserve, brain reserve, and brain maintenance, aiming to provide a common language for studying resilience to age- and disease-related brain changes; no mechanistic or outcome data on neuroplasticity or stroke recovery are reported.",
          "pmid": "30222945",
          "title": "Whitepaper: Defining and investigating cognitive reserve, brain reserve, and brain maintenance.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates cardiovascular, heart failure, and renal outcomes of SGLT2 inhibitors in HFrEF and includes subgroup analyses by age, but it does not examine neuroplasticity, frailty, synaptic adaptation, or post-stroke regenerative processes. Age is only a stratification variable for treatment effect, with no mechanistic exploration of age-related neuroplastic changes or stroke recovery.",
          "key_findings": "SGLT2 inhibitors (dapagliflozin and empagliflozin) reduced all-cause death, cardiovascular death, and heart failure hospitalizations, with benefits generally consistent across age, sex, diabetes status, ARNI use, and baseline eGFR. No data are presented on neural recovery, neuroplasticity, frailty, or stroke outcomes, and age is not mechanistically linked to neuroplastic changes in the analysis.",
          "pmid": "32877652",
          "title": "SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses how pregnancy and motherhood affect cognition, neuroplasticity, neuroimmune signaling, and stroke outcomes, but it does not address age-related reductions in neuroplasticity, frailty, or regenerative processes after stroke specifically. It focuses on reproductive history and female-specific factors rather than aging mechanisms per se.",
          "key_findings": "Motherhood is associated with short- and long-term changes in brain function, cognition, neuroplasticity, and neuroimmune signaling; parity may influence brain health, neurodegenerative diseases, stroke outcomes, and responses to hormone and antidepressant treatments; pregnancy and motherhood are highlighted as important factors in understanding female brain aging.",
          "pmid": "30826374",
          "title": "The long and short term effects of motherhood on the brain.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract examines how exoskeleton-assisted gait training influences balance, gait, and cortical activation (neuroplastic changes) in subacute stroke patients, but it does not analyze or stratify results by age, nor does it address frailty or age-related differences in neuroplasticity or regenerative capacity. Therefore, it neither supports nor contradicts the specific mechanism that older age is associated with reduced neuroplasticity and frailty affecting post-stroke synaptic adaptation.",
          "key_findings": "Robot-assisted training led to greater improvements than conventional therapy in balance (BBS), lower-limb motor function (FMA-LE), functional ambulation (FAC), and activities of daily living (mBI). Both groups improved gait speed and cadence, while only the robot group improved stride length, support phase, and toe-off angle on the affected side. Functional near-infrared spectroscopy showed increased neural activity in the ipsilesional motor area and bilateral prefrontal cortex after robot-assisted training, indicating training-related neuroplastic changes, but without any analysis related to patient age or frailty.",
          "pmid": "39639336",
          "title": "Effectiveness of unilateral lower-limb exoskeleton robot on balance and gait recovery and neuroplasticity in patients with subacute stroke: a randomized controlled trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates whether levodopa, a dopaminergic agent thought to stimulate neuroplasticity, improves motor recovery after stroke, and finds no benefit. However, it does not analyze outcomes by age, does not measure neuroplasticity directly, and does not address how older age, frailty, or reduced regenerative capacity modify neuroplastic responses. Therefore it provides no direct evidence for or against the specific mechanism that older age is associated with reduced neuroplasticity and frailty impacting post-stroke synaptic adaptation.",
          "key_findings": "In a randomized, double-blind trial of 610 patients with acute stroke (median age 73 years), levodopa/carbidopa vs placebo for 39 days added to standardized task-oriented rehabilitation did not significantly improve motor recovery at 3 months (mean FMA difference \u22120.90 points; 95% CI \u22123.78 to 1.98; P = .54). Serious adverse events were similar between groups. The study does not report age-stratified effects or measures of neuroplasticity, frailty, or synaptic adaptation.",
          "pmid": "40982270",
          "title": "Levodopa Added to Stroke Rehabilitation: The ESTREL Randomized Clinical Trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates how heat adaptation training affects physiological, perceptual, and performance outcomes during exercise in the heat. It does not examine age-related differences, neuroplasticity, frailty, synaptic adaptation, or regenerative processes after stroke, nor does it involve a stroke population. Therefore it neither supports nor contradicts the proposed age-related neuroplasticity mechanism.",
          "key_findings": "Heat adaptation regimens of 7\u201314+ days moderately improve exercise performance and capacity in the heat, reduce core temperature before and during exercise, help maintain cardiovascular stability, enhance heat-loss pathways, and improve perceptual measures such as ratings of perceived exertion and thermal sensation. Some limited evidence suggests effects on oxygen consumption, glycogen sparing, lactate threshold, and lactate concentrations, but no data relate to age-associated neuroplasticity or post-stroke recovery.",
          "pmid": "27106556",
          "title": "The Effects of Heat Adaptation on Physiology, Perception and Exercise Performance in the Heat: A Meta-Analysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract concerns guidelines for autophagy assays and does not address age-related changes in neuroplasticity, frailty, synaptic adaptation, or regenerative processes after stroke.",
          "key_findings": "The abstract (title only) indicates a methodological/guideline paper on the use and interpretation of autophagy monitoring assays; it provides no data or discussion on aging, neuroplasticity, frailty, or post-stroke recovery.",
          "pmid": "26799652",
          "title": "Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition).",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract reports baseline characteristics of heart failure patients in a mitral regurgitation device trial, including age and cardiac parameters, but does not evaluate neuroplasticity, frailty, synaptic adaptation, or post-stroke regenerative processes. Age is mentioned only as a demographic descriptor without any mechanistic link to neuroplasticity or stroke recovery.",
          "key_findings": "Mean age of RESHAPE-HF2 patients was 70\u00b110 years; patients had symptomatic heart failure with functional mitral regurgitation and various cardiac and renal parameters described. No data on neuroplasticity, stroke outcomes, or regenerative neurological processes are provided.",
          "pmid": "38847420",
          "title": "Percutaneous repair of moderate-to-severe or severe functional mitral regurgitation in patients with symptomatic heart failure: Baseline characteristics of patients in the RESHAPE-HF2 trial and comparison to COAPT and MITRA-FR trials.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract concerns intravenous iron therapy and exercise capacity/adverse events in older patients with HFpEF and iron deficiency. It does not examine neuroplasticity, frailty-related regenerative capacity, synaptic adaptation, or post-stroke recovery, nor does it analyze age-related changes in these processes. Therefore, it neither supports nor contradicts the proposed mechanism about reduced neuroplasticity and frailty after stroke in older age.",
          "key_findings": "In a small, prematurely terminated randomized double-blind trial (median age 80) of patients with HFpEF and iron deficiency, intravenous ferric carboxymaltose improved 6-minute walking distance by a least squares mean difference of 49 m versus placebo and was associated with fewer serious adverse events, while effects on symptoms and quality of life were inconclusive due to limited power.",
          "pmid": "39185895",
          "title": "Ferric carboxymaltose and exercise capacity in heart failure with preserved ejection fraction and iron deficiency: the FAIR-HFpEF trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The study shows that exoskeleton-based gait training enhances neuroplasticity and motor function after stroke, but it does not examine the influence of older age, reduced neuroplasticity in older vs younger patients, frailty, or age-related differences in synaptic or regenerative responses. Age is only reported descriptively and not analyzed as a mechanistic factor.",
          "key_findings": "In stroke patients aged 18\u201375, exoskeleton robot walking training improved cortical excitability (decreased resting motor threshold, increased motor-evoked potential amplitude and recruitment curve slope) and lower limb motor outcomes (better 6-min walk test and knee flexion co-contraction ratio) compared with conventional training, with significant correlations between neurophysiological and gait/EMG measures; no age-related analyses were performed.",
          "pmid": "40319228",
          "title": "Effects of exoskeleton rehabilitation robot training on neuroplasticity and lower limb motor function in patients with stroke.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract focuses on methodological guidelines for monitoring autophagy across systems. It does not address age-related changes, neuroplasticity, frailty, synaptic adaptation, regenerative processes, or stroke outcomes, so it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "The article outlines guidelines for selecting and interpreting assays to monitor autophagy, emphasizing the need for multiple techniques, consideration of canonical and noncanonical autophagy, and the pleiotropic roles of autophagy-related proteins in other pathways such as apoptosis.",
          "pmid": "33634751",
          "title": "Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)<sup>1</sup>.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses aortic stenosis, its haemostatic interactions, and thrombotic complications, but does not address age-related differences in neuroplasticity, frailty, synaptic adaptation, or regenerative processes after stroke. Although it mentions that aortic stenosis affects older adults and is a risk factor for thromboembolic stroke, it provides no mechanistic information about how older age alters neuroplastic recovery post-stroke.",
          "key_findings": "Aortic stenosis affects over 10% of people older than 80; it is a major risk factor for heart failure, thromboembolic stroke, and death. The pathogenesis involves endothelial dysfunction, inflammation, fibrosis, and calcification, with an interplay between platelets, coagulation, von Willebrand factor, and microparticles. Post\u2013transcatheter aortic valve replacement, persistent biological activity of the native valve can lead to microthrombosis and impact valve function. No data are presented regarding neuroplasticity, frailty, or post-stroke regenerative processes.",
          "pmid": "36537038",
          "title": "Aortic stenosis and the haemostatic system.",
          "analysis_method": "llm"
        },
        {
          "stance": "support",
          "confidence": "high",
          "reasoning": "The abstract explicitly links aging with a decline in regenerative abilities in vertebrate tissues, including the nervous system, and attributes this to loss of stem/progenitor cell function and impaired reparative processes. This aligns with the proposed mechanism that older age is associated with reduced neuroplasticity and regenerative capacity after injuries such as stroke, even though stroke is only mentioned as an example of age-related disease rather than directly studied.",
          "key_findings": "1) Aging is marked by molecular and cellular changes (DNA damage, oxidative stress, altered systemic environment) that lead to cell demise and reduced reparative activities. 2) Vertebrate regeneration declines with age due to loss of stem/progenitor cell function. 3) The review discusses aging effects on regeneration in multiple organs including the nervous system, and notes these tissues are involved in age-associated diseases such as stroke and cognitive impairment.",
          "pmid": "24512711",
          "title": "Aging and regeneration in vertebrates.",
          "analysis_method": "llm"
        },
        {
          "stance": "support",
          "confidence": "medium",
          "reasoning": "The mechanism proposes that older age is associated with reduced neuroplasticity and regenerative capacity after stroke. The abstract explicitly states that the plasticity of the ischemic brain is influenced by aging and reports that chronic fluoxetine treatment did not reverse age\u2011dependent suppression of cell proliferation in the dentate gyrus. This directly supports the idea that aging is linked to diminished neuroplastic responses and that this age-related reduction is resistant to a pro\u2011plasticity intervention, aligning with reduced regenerative processes in older brains.",
          "key_findings": "1) The plasticity of the ischemic brain is influenced by aging and pharmacotherapy. 2) Chronic treatment with fluoxetine did not reverse age-dependent suppression of proliferating cells in the dentate gyrus after stroke. 3) Fluoxetine enhances certain aspects of neuroplasticity (e.g., increased excitability of mature granule cells, axonal/dendritic reorganization, neurogenesis/angiogenesis) but these effects do not overcome the age-related decline in proliferation.",
          "pmid": "28854520",
          "title": "Neuroplasticity and behavioral effects of fluoxetine after experimental stroke.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses mitochondrial dysfunction in migraine, its genetics, and related disorders including stroke, but does not address age-related changes in neuroplasticity, frailty, synaptic adaptation, or regenerative processes after stroke. There is no examination of how older age modifies post-stroke neuroplasticity or recovery, so it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "The review covers: (1) mitochondrial dysfunction (mtDNA polymorphisms, oxidative stress, nuclear DNA mutations) as a potential mechanism in migraine; (2) correlations of migraine with conditions such as MELAS, ischemic stroke, and hypertension; and (3) therapeutic supplements for migraine management. Age-related neuroplasticity or frailty and their impact on post-stroke synaptic or regenerative processes are not discussed.",
          "pmid": "35478208",
          "title": "Current perspectives on mitochondrial dysfunction in migraine.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract examines cortical thickness differences and age associations in individuals at clinical high risk for psychosis, not stroke. It does not address neuroplasticity, frailty, synaptic adaptation, or regenerative processes after stroke, nor does it focus on older age populations; thus it neither supports nor conflicts with the proposed mechanism.",
          "key_findings": "Individuals at clinical high risk for psychosis showed widespread lower cortical thickness compared with healthy controls, and specific cortical regions (fusiform, superior temporal, paracentral) with lower thickness were associated with later psychosis. Some regions showed abnormal age associations in the high-risk converters. These findings relate to neurodevelopmental and psychosis risk processes, not age-related changes in neuroplasticity or post-stroke recovery.",
          "pmid": "33950164",
          "title": "Association of Structural Magnetic Resonance Imaging Measures With Psychosis Onset in Individuals at Clinical High Risk for Developing Psychosis: An ENIGMA Working Group Mega-analysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses age-related changes in cardiovascular and peripheral oxygen transport, VO2max, stroke volume, and endurance performance, as well as their modification with training. It does not address neuroplasticity, synaptic adaptation, regenerative neural processes, or post-stroke recovery, which are central to the proposed mechanism.",
          "key_findings": "With aging, there is a central limitation in VO2max that can be modified by training; peripheral adaptations occur and stroke volume may increase via improved diastolic filling; in young and old, peripheral machinery is matched to growth and loss of muscle mass; anaerobic threshold is relatively low in children and high in older adults. None of these findings pertain to neural plasticity or post-stroke regenerative processes.",
          "pmid": "9916179",
          "title": "The gas transporting systems: limits and modifications with age and training.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses cognitive reserve and resilience in the context of neurodegenerative diseases and dementia, focusing on epidemiological, lifestyle, genetic, and mechanistic aspects of reserve. It does not address age-related changes in neuroplasticity, frailty, or synaptic/regenerative responses after stroke specifically, nor does it provide data on how older age affects neuroplastic adaptation post-stroke.",
          "key_findings": "The paper offers a consensus on concepts and mechanisms of reserve against neurodegenerative disease, including potential brain functional and structural bases, lifestyle and genetic factors, and the need for harmonized research and data sharing. It does not examine age-related reductions in neuroplasticity, frailty, or post-stroke synaptic/regenerative processes.",
          "pmid": "30808345",
          "title": "Translational research on reserve against neurodegenerative disease: consensus report of the International Conference on Cognitive Reserve in the Dementias and the Alzheimer's Association Reserve, Resilience and Protective Factors Professional Interest Area working groups.",
          "analysis_method": "llm"
        }
      ]
    },
    {
      "feature_name": "Age",
      "mechanism": {
        "mechanism_type": "biological",
        "description": "Age-related vascular changes alter the thrombolysis risk-benefit ratio by increasing hemorrhagic transformation risks.",
        "evidence_level": "strong"
      },
      "query": "(stroke OR alteplase OR thrombolysis OR \"ischemic stroke\") AND \"Age\" AND (\"pathophysiology\" OR \"mechanism\" OR \"causal\" OR \"etiology\" OR \"interaction\") AND (\"transformation\" OR \"thrombolysis\" OR \"hemorrhagic\") AND (Clinical Trial[PT] OR Review[PT] OR Meta-Analysis[PT])",
      "total_abstracts": 20,
      "support_count": 0,
      "conflict_count": 1,
      "neutral_count": 19,
      "support_percentage": 0.0,
      "conflict_percentage": 5.0,
      "support_ratio": 0.0,
      "abstracts_analyzed": [
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses epidemiology, risk factors, demographics, and outcomes of premature (young) stroke, but does not address age-related vascular changes, thrombolysis, or hemorrhagic transformation risk. Therefore it neither supports nor conflicts with the proposed mechanism about how aging vasculature alters thrombolysis risk-benefit balance.",
          "key_findings": "1) Recent increases in ischemic and hemorrhagic strokes among young patients. 2) Strokes in the young are heterogeneous and often cryptogenic. 3) Sex distribution and risk factors change with age within the young adult range (more women <35, more men >45 with rising traditional vascular risk factors). 4) Higher incidence in minority and socioeconomically disadvantaged populations, with concern for disparities in recognition and access to care. 5) Premature strokes have disproportionate impact on quality of life and productivity. None of these findings address age-related vascular changes or thrombolysis-related hemorrhagic transformation.",
          "pmid": "36374365",
          "title": "A Contemporary Review of Epidemiology, Risk Factors, Etiology, and Outcomes of Premature Stroke.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses post-stroke movement disorders, their clinical spectrum, and general pathophysiological mechanisms such as neuronal plasticity, functional diaschisis, and age-related differences in brain metabolism. It does not address thrombolysis, vascular changes related to aging, hemorrhagic transformation, or the risk-benefit ratio of thrombolytic therapy. Therefore it neither supports nor conflicts with the proposed mechanism.",
          "key_findings": "Post-stroke movement disorders occur in 1\u20134% of strokes, involving structures like the basal ganglia and thalamus. Types include hemichorea-hemiballism, dystonia, tremor, myoclonus, asterixis, stereotypies, and vascular parkinsonism. Proposed mechanisms involve neuronal plasticity, functional diaschisis, and age-related metabolic differences, and there are no specific management guidelines due to heterogeneity.",
          "pmid": "33904435",
          "title": "Post-stroke Movement Disorders: Clinical Spectrum, Pathogenesis, and Management.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The trial reports overall age distribution and hemorrhagic outcomes with two thrombolytic agents but does not analyze how age-related vascular changes modify hemorrhagic transformation risk or the thrombolysis risk-benefit ratio. No age-stratified safety analyses, vascular aging markers, or mechanistic assessments pertinent to age-related vascular changes are presented.",
          "key_findings": "In a randomized trial of 1600 acute ischemic stroke patients (median age 74), tenecteplase was non-inferior to alteplase for good functional outcome (mRS 0\u20131 at 90\u2013120 days: 36.9% vs 34.8%; risk difference 2.1%, 95% CI \u22122.6 to 6.9). Symptomatic intracerebral hemorrhage at 24 h occurred in 3.4% vs 3.2%, and 90-day mortality was 15.3% vs 15.4% for tenecteplase vs alteplase, respectively. The study does not report outcomes stratified by age or vascular aging parameters, nor does it examine how age-related vascular changes alter hemorrhagic risk from thrombolysis.",
          "pmid": "35779553",
          "title": "Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract compares clinical characteristics, thrombolysis rates, hemorrhage, mortality, and outcomes between ischemic strokes and stroke mimics, noting that mimics are younger and have fewer vascular risk factors. However, it does not analyze age-related vascular changes as a mechanistic cause of increased hemorrhagic transformation risk, nor does it quantify how age or vascular aging directly alters the thrombolysis risk-benefit ratio.",
          "key_findings": "Stroke mimics had younger age and fewer vascular risk factors than true ischemic stroke patients; overall intracranial hemorrhage occurred in 9.4% of stroke vs. 0.7% of stroke mimic patients, and thrombolysis was given in 61.7% of stroke vs. 26.3% of mimics. The study does not specifically evaluate age-related vascular changes or their mechanistic impact on hemorrhagic transformation risk after thrombolysis.",
          "pmid": "34656244",
          "title": "Ischemic stroke mimics: A comprehensive review.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses stroke epidemiology, recanalization therapies, and neuroprotective strategies in general but does not address age-related vascular changes, hemorrhagic transformation risk, or how age alters the thrombolysis risk-benefit ratio.",
          "key_findings": "The review notes the growing elderly population and the increasing incidence of stroke, outlines current ischemic stroke treatments including pharmacological and mechanical thrombolysis, and focuses on the need for neuroprotective agents and combinational therapies. It does not provide data or discussion on age-related vascular changes or hemorrhagic complications of thrombolysis.",
          "pmid": "33144066",
          "title": "Emerging neuroprotective strategies for the treatment of ischemic stroke: An overview of clinical and preclinical studies.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates fibrinolytic (thrombolytic) therapy versus placebo in intermediate\u2011risk pulmonary embolism and reports increased major bleeding and hemorrhagic stroke, but it does not analyze age-related vascular changes, age subgroups, or how aging vasculature modifies the risk\u2013benefit ratio of thrombolysis. Therefore it neither supports nor contradicts the specific mechanism that age-related vascular changes alter thrombolysis risk\u2013benefit by increasing hemorrhagic transformation.",
          "key_findings": "In a randomized trial of 1005 normotensive patients with intermediate\u2011risk pulmonary embolism, tenecteplase plus heparin reduced the composite of death or hemodynamic decompensation at 7 days (2.6% vs 5.6%; OR 0.44; P=0.02) but did not reduce mortality alone. Tenecteplase markedly increased major extracranial bleeding (6.3% vs 1.2%; P<0.001) and stroke (2.4% vs 0.2%; P=0.003), predominantly hemorrhagic. The study does not report effects stratified by age or vascular aging parameters.",
          "pmid": "24716681",
          "title": "Fibrinolysis for patients with intermediate-risk pulmonary embolism.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses thrombolysis in pediatric stroke, reporting a low rate of intracranial hemorrhage, but does not examine age-related vascular changes or compare thrombolysis risk-benefit profiles between children and older adults. It therefore does not provide direct evidence about whether age-related vascular changes increase hemorrhagic transformation risk or alter the thrombolysis risk-benefit ratio.",
          "key_findings": "In children with acute ischemic stroke, thrombolysis is reported to have a low risk (2.1%) of intracranial hemorrhage, and institutional protocols can reduce time to neuroimaging and hyperacute therapies. No mechanisms involving age-related vascular changes or comparative hemorrhagic transformation risks by age are discussed.",
          "pmid": "34327611",
          "title": "Acute ischemic stroke in childhood: a comprehensive review.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract examines predictors of hemorrhagic transformation and symptomatic intracranial hemorrhage after thrombectomy, focusing on NIHSS, glucose, anticoagulant history, and procedure-related factors, and reports no effect of alteplase. It does not analyze age-related vascular changes or age as a determinant of hemorrhagic transformation risk, nor does it address how aging alters the thrombolysis risk-benefit ratio.",
          "key_findings": "In 633 EVT-treated stroke patients (median age 69), hemorrhagic transformation occurred in 41.2%, symptomatic intracranial hemorrhage (sICH) in 5.4%, and parenchymal hematoma in 13.4%. Higher baseline NIHSS and higher admission glucose predicted sICH overall; in the EVT-alone group, higher NIHSS predicted sICH, while in the combination EVT+alteplase group, prior anticoagulant use, higher glucose, and more than three device passes predicted sICH. Importantly, alteplase treatment did not increase the risk of hemorrhagic transformation, sICH, or parenchymal hematoma after EVT. Age-related vascular changes or age as a risk modifier were not evaluated as primary determinants.",
          "pmid": "34872341",
          "title": "Clinical and Imaging Indicators of Hemorrhagic Transformation in Acute Ischemic Stroke After Endovascular Thrombectomy.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The trial evaluates safety and efficacy of adjunctive intra-arterial tenecteplase after successful endovascular thrombectomy, reporting rates of symptomatic intracranial hemorrhage and mortality, but it does not analyze age-related vascular changes, age subgroups, or how aging vasculature modifies hemorrhagic transformation risk or the thrombolysis risk-benefit ratio.",
          "key_findings": "In 540 patients (median age 69) with large vessel occlusion stroke and eTICI 2c\u20133 after EVT, adjunctive intra-arterial tenecteplase vs no thrombolysis resulted in: (1) similar functional independence at 90 days (mRS 0\u20131: 49.1% vs 44.1%; adjusted RR 1.15, 95% CI 0.97\u20131.36; P=0.11); (2) no significant difference in 90-day mortality (16.0% vs 19.3%; adjusted HR 0.75, 95% CI 0.50\u20131.13; P=0.16); and (3) numerically higher but not statistically significant symptomatic intracranial hemorrhage (6.3% vs 4.4%; adjusted RR 1.43, 95% CI 0.68\u20132.99; P=0.35). The study does not examine the influence of age-related vascular changes on hemorrhagic risk or risk-benefit trade-offs.",
          "pmid": "39804681",
          "title": "Intra-Arterial Tenecteplase Following Endovascular Reperfusion for Large Vessel Occlusion Acute Ischemic Stroke: The POST-TNK Randomized Clinical Trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The trial compares outcomes of endovascular thrombectomy alone versus combined IV alteplase plus thrombectomy, reporting functional independence, symptomatic intracerebral hemorrhage, and mortality, but it does not analyze age-related vascular changes, how age modifies hemorrhagic transformation risk, or how aging alters the thrombolysis risk-benefit ratio. Mean age is given only as a descriptive characteristic, with no age-stratified results or vascular aging measures.",
          "key_findings": "In 234 patients (mean age 68 years) with proximal anterior circulation occlusion within 4.5 hours, endovascular thrombectomy alone was noninferior to IV alteplase plus thrombectomy for 90-day functional independence (54.3% vs 46.6%). Rates of symptomatic intracerebral hemorrhage (6.1% vs 6.8%) and 90-day mortality (17.2% vs 17.8%) did not differ significantly between groups. No specific evaluation of age-related vascular changes or age-dependent hemorrhagic transformation risk was reported.",
          "pmid": "33464335",
          "title": "Effect of Endovascular Treatment Alone vs Intravenous Alteplase Plus Endovascular Treatment on Functional Independence in Patients With Acute Ischemic Stroke: The DEVT Randomized Clinical Trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates safety and efficacy of endovascular treatment versus best medical management in medium/distal vessel occlusions, reporting overall symptomatic intracranial hemorrhage and mortality. It does not analyze age-related vascular changes, does not stratify hemorrhagic transformation risk by age, and does not discuss how aging vasculature alters thrombolysis risk\u2013benefit. Therefore it neither supports nor contradicts the specific mechanism about age-related vascular changes modifying thrombolysis risk\u2013benefit ratio.",
          "key_findings": "In 543 stroke patients with medium/distal vessel occlusions (median age 77), EVT plus best medical treatment showed no significant functional benefit versus best medical treatment alone (mRS common odds ratio 0.90, 95% CI 0.67\u20131.22). All-cause mortality was similar (15.5% vs. 14.0%), and symptomatic intracranial hemorrhage rates were 5.9% with EVT plus medical therapy versus 2.6% with medical therapy alone. Approximately 65.4% received intravenous thrombolysis, but no age-specific vascular or hemorrhagic transformation analyses were reported.",
          "pmid": "39908430",
          "title": "Endovascular Treatment for Stroke Due to Occlusion of Medium or Distal Vessels.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates time-dependent functional benefit of IV thrombolysis plus thrombectomy versus thrombectomy alone but does not analyze age-related vascular changes, hemorrhagic transformation risk, or how age modifies the thrombolysis risk-benefit ratio. Age is only reported as a baseline characteristic, without stratified outcomes or mechanistic discussion of vascular aging or bleeding risk.",
          "key_findings": "In a meta-analysis of 6 RCTs (n=2313, median age 71), the benefit of IV thrombolysis plus thrombectomy versus thrombectomy alone decreased with longer onset-to-expected-IVT time (ratio of adjusted common OR per 1-hour delay 0.84, 95% CI 0.72-0.97). The adjusted common OR for better mRS outcome was 1.49 at 1 hour, 1.25 at 2 hours, and 1.04 at 3 hours, with predicted absolute risk differences in mRS 0\u20132 of 9%, 5%, and 1% respectively. Benefit was not statistically significant after about 2 hours 20 minutes and crossed the null around 3 hours 14 minutes. No data are presented on hemorrhagic transformation rates by age or on age-related vascular changes.",
          "pmid": "38324409",
          "title": "Time to Treatment With Intravenous Thrombolysis Before Thrombectomy and Functional Outcomes in Acute Ischemic Stroke: A Meta-Analysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The trial evaluates remote ischemic conditioning for acute stroke and its impact on functional outcome and adverse events but does not analyze age-related vascular changes, thrombolysis, or hemorrhagic transformation risk. No data are presented on how age modifies thrombolysis risk\u2013benefit or hemorrhagic complications, so it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "In 1500 patients with suspected acute stroke (median age 71), remote ischemic conditioning started prehospital and continued in-hospital did not improve 90-day functional outcome compared with sham (mRS shift OR 0.95; 95% CI 0.75\u20131.20) and did not increase serious adverse events. The study did not examine thrombolytic therapy effects, age-related vascular changes, or hemorrhagic transformation rates.",
          "pmid": "37787796",
          "title": "Remote Ischemic Conditioning for Acute Stroke: The RESIST Randomized Clinical Trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract examines different post-thrombectomy blood pressure targets and their effects on functional outcome, hemorrhagic transformation, and mortality, but it does not analyze age-related vascular changes or how aging alters the thrombolysis risk-benefit ratio. Age is only reported as a baseline characteristic and not explored as a mechanistic modifier of hemorrhagic risk.",
          "key_findings": "In patients (mean age 73 years) with successful reperfusion after endovascular thrombectomy, intensive BP lowering (SBP <140 mmHg) vs conventional (140\u2013180 mmHg) resulted in worse functional independence at 3 months (39.4% vs 54.4%; adjusted OR 0.56) without significant differences in symptomatic intracerebral hemorrhage (9.0% vs 8.1%) or stroke-related death at 3 months (7.7% vs 5.4%). The study does not stratify results by age or vascular aging parameters, nor does it assess how age-related vascular changes affect hemorrhagic transformation risk under thrombolytic or thrombectomy treatment.",
          "pmid": "37668619",
          "title": "Intensive vs Conventional Blood Pressure Lowering After Endovascular Thrombectomy in Acute Ischemic Stroke: The OPTIMAL-BP Randomized Clinical Trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract studies very early blood-pressure lowering in suspected acute stroke and its differential effect on outcomes in hemorrhagic vs ischemic stroke. It does not examine age-related vascular changes, thrombolysis use, or hemorrhagic transformation risk after thrombolysis. Therefore, it neither supports nor contradicts the specific mechanism that age-related vascular changes alter the thrombolysis risk-benefit ratio by increasing hemorrhagic transformation risks.",
          "key_findings": "In a randomized trial of 2404 patients with suspected acute stroke (mean age 70), prehospital intensive systolic blood pressure reduction (target 130\u2013140 mm Hg) versus usual care showed: (1) no overall difference in 90-day functional outcome or serious adverse events; (2) among patients later confirmed to have hemorrhagic stroke, lower prehospital blood pressure was associated with better functional outcome (common OR 0.75, 95% CI 0.60\u20130.92); (3) among patients with cerebral ischemia, lower prehospital blood pressure was associated with worse functional outcome (common OR 1.30, 95% CI 1.06\u20131.60). The study does not address age-related vascular changes or thrombolysis-related hemorrhagic transformation.",
          "pmid": "38752650",
          "title": "Intensive Ambulance-Delivered Blood-Pressure Reduction in Hyperacute Stroke.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates the impact of evolocumab on major adverse cardiovascular events and reports no excess in safety events overall, but it does not address thrombolysis, hemorrhagic transformation, or age-related vascular changes in the context of thrombolytic therapy. Therefore it neither supports nor contradicts the proposed mechanism about age-related vascular changes altering the thrombolysis risk-benefit ratio.",
          "key_findings": "Evolocumab reduced 3-point and 4-point MACE in patients without prior myocardial infarction or stroke, with hazard ratios of 0.75 and 0.81 respectively, and no between-group difference in overall safety events. Stroke outcomes reported are ischemic stroke as part of composite endpoints and do not concern thrombolysis or hemorrhagic transformation risk, nor age-related vascular changes in that context.",
          "pmid": "41211925",
          "title": "Evolocumab in Patients without a Previous Myocardial Infarction or Stroke.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses stroke epidemiology, causes, and management in young patients, focusing on non-atherosclerotic etiologies and lack of conventional vascular risk factors. It does not address age-related vascular changes, thrombolysis, hemorrhagic transformation, or how aging alters the risk-benefit ratio of thrombolysis, so it neither supports nor conflicts with the proposed mechanism.",
          "key_findings": "In young stroke patients without conventional vascular risk factors, there is increased prevalence of cardio-embolism (e.g., PFO/atrial septal aneurysm), non-atherosclerotic vasculopathy (e.g., dissection), thrombophilia, and other unusual causes; evidence-based guidelines for these uncommon etiologies are lacking.",
          "pmid": "31768660",
          "title": "Stroke in the Young: a Global Update.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates clinical outcomes (recurrent ischemic stroke and mortality) in atrial fibrillation patients who experience ischemic stroke while on oral anticoagulation. It does not analyze age-related vascular changes, hemorrhagic transformation, or the risk-benefit ratio of thrombolysis. There is no discussion of thrombolytic therapy, intracranial hemorrhage, or how age modifies bleeding risk, so it neither supports nor conflicts with the proposed mechanism.",
          "key_findings": "Among 1163 AF patients with ischemic stroke while on oral anticoagulation (median age 73 years), the 1-year cumulative incidence of recurrent ischemic stroke was about 7%, and 3\u2011month mortality was about 12%. The study concludes these patients are at increased risk of recurrent ischemic stroke and death and have an unmet medical need, but provides no data on thrombolysis, hemorrhagic transformation, or age-related vascular effects.",
          "pmid": "37038327",
          "title": "Outcomes of patients with atrial fibrillation and ischemic stroke while on oral anticoagulation.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The study compares safety and efficacy of tenecteplase vs alteplase in acute ischaemic stroke but does not analyze how age-related vascular changes modify hemorrhagic transformation risk or the thrombolysis risk-benefit ratio. Age is only used as a balancing variable in randomization, with no age-stratified hemorrhage outcomes or vascular aging mechanisms examined.",
          "key_findings": "In adults with acute ischaemic stroke treated within 4.5 hours, tenecteplase and alteplase showed similar penumbra salvage and no significant differences in symptomatic or total intracerebral hemorrhage or serious adverse events. The trial did not investigate the impact of age-related vascular changes on hemorrhagic transformation or treatment risk-benefit.",
          "pmid": "25726502",
          "title": "Alteplase versus tenecteplase for thrombolysis after ischaemic stroke (ATTEST): a phase 2, randomised, open-label, blinded endpoint study.",
          "analysis_method": "llm"
        },
        {
          "stance": "conflict",
          "confidence": "medium",
          "reasoning": "The proposed mechanism posits that age-related vascular changes increase hemorrhagic transformation risk and thereby alter (worsen) the thrombolysis risk-benefit ratio in older patients. This review directly reports that participants over 80 years old benefited equally to those under 80 from thrombolysis, particularly when treated within three hours, implying that advanced age did not worsen the overall risk-benefit balance. Although the abstract acknowledges increased intracranial hemorrhage risk overall, it does not report a higher hemorrhage risk or a poorer net outcome specifically in older versus younger patients; instead, it suggests comparable benefit, which runs counter to the idea that age-related vascular changes meaningfully deteriorate the thrombolysis risk-benefit ratio.",
          "key_findings": "1) Thrombolytic therapy increased symptomatic intracranial hemorrhage and early mortality overall but reduced death or dependency at 3\u20136 months. 2) Treatment within three hours improved outcomes without increasing mortality. 3) Crucially, the abstract states: 'Participants aged over 80 years benefited equally to those aged under 80 years, particularly if treated within three hours of stroke.' 4) No age-specific excess bleeding risk or worse net outcomes are reported for >80 vs <80, suggesting that advanced age did not diminish the overall benefit of thrombolysis in the data summarized.",
          "pmid": "25072528",
          "title": "Thrombolysis for acute ischaemic stroke.",
          "analysis_method": "llm"
        }
      ]
    },
    {
      "feature_name": "Age",
      "mechanism": {
        "mechanism_type": "pharmacological",
        "description": "Age-related alterations in metabolism and clearance of drugs due to liver and kidney function changes.",
        "evidence_level": "moderate"
      },
      "query": "(stroke OR alteplase OR thrombolysis OR \"ischemic stroke\") AND \"Age\" AND (\"pharmacokinetics\" OR \"pharmacodynamics\" OR \"dose-response\" OR \"clearance\") AND (\"alterations\" OR \"metabolism\" OR \"clearance\") AND (Clinical Trial[PT] OR Review[PT] OR Meta-Analysis[PT])",
      "total_abstracts": 19,
      "support_count": 1,
      "conflict_count": 0,
      "neutral_count": 18,
      "support_percentage": 5.263157894736842,
      "conflict_percentage": 0.0,
      "support_ratio": 0.05263157894736842,
      "abstracts_analyzed": [
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses traumatic brain injury epidemiology, management, biomarkers, imaging, precision medicine, and outcome assessment, with some focus on older adults and comorbidities, but it does not address pharmacokinetics, drug metabolism, liver or kidney function, or age-related changes in drug clearance. Therefore, it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "The abstract notes that TBI incidence in high-income countries is high among older people (\u226565 years) with comorbidities, highlights that little evidence exists to guide treatment in older patients, and emphasizes precision medicine and comparative-effectiveness research. However, it does not provide data or discussion on age-related hepatic or renal changes affecting drug metabolism or clearance.",
          "pmid": "36183712",
          "title": "Traumatic brain injury: progress and challenges in prevention, clinical care, and research.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates efficacy and safety of DOACs versus warfarin and tests interactions by age, sex, weight, prior VKA use, and creatinine clearance, but it does not examine or attribute effects to age-related changes in hepatic or renal drug metabolism/clearance. The interaction by age describes outcome differences, not pharmacokinetic mechanisms, and renal function (creatinine clearance) is treated as a broad covariate rather than as an age-related metabolic/clearance mechanism.",
          "key_findings": "Standard- and lower-dose DOACs versus warfarin show consistent treatment effects across age and sex for stroke/systemic embolism and death, with younger patients deriving greater benefit in continuous covariate analysis. DOACs, especially lower-dose, have lower risks of intracranial bleeding and major bleeding versus warfarin. Standard-dose DOACs are favored in patients with no prior vitamin K antagonist use and lower creatinine clearance, and in patients with lower body weight for major bleeding. No explicit analysis links these results to age-related changes in liver or kidney drug metabolism or clearance.",
          "pmid": "34985309",
          "title": "Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses tyrosine kinase inhibitor use, efficacy, adverse effects, and general considerations for therapy selection and adherence in chronic myeloid leukemia, but it does not address age-related changes in drug metabolism or clearance, nor liver/kidney function differences with age or their impact on TKI pharmacokinetics.",
          "key_findings": "The abstract notes that multiple BCR::ABL1 TKIs are approved, have similar survival benefits, and display various agent-specific toxicities (e.g., myelosuppression, pleural effusion, arterio-occlusive events, gastrointestinal disturbance, pancreatitis), and emphasizes adherence and adverse-effect\u2013based drug selection. No mention is made of age-related hepatic or renal function changes or altered metabolism/clearance of TKIs.",
          "pmid": "40094679",
          "title": "Chronic Myeloid Leukemia: A Review.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses Chinese medicines for diabetic nephropathy, focusing on reno-protective mechanisms such as modulation of glucose/lipid metabolism, antioxidation, anti-inflammation, anti-fibrosis, and podocyte protection. It does not address age-related changes in drug metabolism or clearance, nor liver or kidney function\u2013driven pharmacokinetic alterations in older adults.",
          "key_findings": "Chinese medicines show multi-target reno-protective effects in diabetic nephropathy through pathways related to metabolism regulation, antioxidation, anti-inflammation, anti-fibrosis, and podocyte protection, based on clinical trials and mechanistic studies. No mention is made of age-related pharmacokinetic changes or altered drug metabolism/clearance.",
          "pmid": "34589395",
          "title": "Clinical efficacies, underlying mechanisms and molecular targets of Chinese medicines for diabetic nephropathy treatment and management.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract reports a phase 2 trial of the factor XIa inhibitor milvexian in mostly older adults but does not evaluate age-related changes in drug metabolism or clearance, nor does it analyze outcomes by liver or kidney function or age-based pharmacokinetics/pharmacodynamics. It focuses on efficacy and bleeding outcomes across fixed doses, not on organ-function\u2013mediated metabolic differences.",
          "key_findings": "Milvexian, an oral small-molecule factor XIa inhibitor, was tested at multiple doses versus placebo in patients aged \u226540 years (median age 71) with recent ischaemic stroke or TIA. No significant dose-response was observed for the composite endpoint of ischaemic stroke or covert brain infarct, and no apparent dose-response for major bleeding. The study does not report pharmacokinetic data, hepatic/renal function effects on milvexian handling, or any age-stratified metabolism or clearance analyses.",
          "pmid": "38101902",
          "title": "Safety and efficacy of factor XIa inhibition with milvexian for secondary stroke prevention (AXIOMATIC-SSP): a phase 2, international, randomised, double-blind, placebo-controlled, dose-finding trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses age-related changes in neurovascular structure and function (e.g., impaired blood\u2013brain exchange and clearance of proteins), but it does not address systemic hepatic or renal function, drug metabolism, or pharmacokinetics. Therefore it neither supports nor contradicts age-related alterations in drug metabolism and clearance due to liver and kidney changes.",
          "key_findings": "Neurovascular aging leads to structural and functional changes in brain vessels, impairing oxygen and glucose delivery, disrupting endothelial transport for blood\u2013brain exchange, reducing clearance of potentially toxic proteins, weakening immune surveillance, and limiting growth factor supply; these changes are linked to stroke, vascular cognitive impairment, and Alzheimer\u2019s disease.",
          "pmid": "39788087",
          "title": "The pathobiology of neurovascular aging.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The study evaluates tolerability, dosing, clinical endpoints, and quality-of-life effects of vericiguat in older HFpEF patients but does not analyze age-related changes in drug metabolism or clearance, nor liver or kidney function\u2013dependent pharmacokinetics or pharmacodynamics.",
          "key_findings": "Vericiguat at various doses over 12 weeks in HFpEF patients (mean age 73) was well tolerated, showed no significant change vs placebo in NT-proBNP or left atrial volume, had similar adverse event rates and blood pressure effects to placebo, and improved quality-of-life scores at 10 mg. No data on age-related pharmacokinetic differences, liver/kidney function\u2013related clearance, or metabolism were reported.",
          "pmid": "28369340",
          "title": "Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract examines the association between the TyG-BMI index (a surrogate of insulin resistance) and incidence of cardiovascular disease. It does not address age-related changes in drug metabolism or clearance, nor liver/kidney function in the context of pharmacokinetics. Therefore it neither supports nor contradicts the proposed pharmacological mechanism.",
          "key_findings": "Higher TyG-BMI index is associated with increased risk of cardiovascular diseases, coronary artery disease, and stroke in individuals without baseline CVD, with a roughly linear dose-response relationship and no significant modification by gender, follow-up duration, sample size, or mean age.",
          "pmid": "39844258",
          "title": "Triglyceride-glucose-body mass index and the incidence of cardiovascular diseases: a meta-analysis of cohort studies.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates clinical efficacy and safety of GLP-1 receptor agonists in people with chronic kidney disease and diabetes but does not analyze age-related changes in drug metabolism or clearance linked to liver or kidney function, nor does it stratify outcomes by age-related pharmacokinetic differences. It focuses on outcomes (mortality, MACE, kidney failure, hypoglycemia) rather than mechanistic alterations in metabolism or clearance with aging.",
          "key_findings": "In adults with type 2 diabetes and CKD (median age 66), GLP-1 receptor agonists vs placebo probably reduce all-cause mortality and major cardiovascular events, have little or no effect on kidney failure or composite kidney outcomes, and may have little or no effect on severe hypoglycemia; no mechanistic pharmacokinetic analyses of age-related metabolism or clearance are reported.",
          "pmid": "39963952",
          "title": "Glucagon-like peptide 1 (GLP-1) receptor agonists for people with chronic kidney disease and diabetes.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates efficacy, safety, pharmacodynamics, and pharmacokinetics of HU6 in obese HFpEF patients, focusing on weight loss and functional outcomes. It does not analyze or report age-related changes in drug metabolism or clearance, nor does it relate outcomes to liver or kidney function changes across age. Therefore, it neither supports nor contradicts the proposed age-related pharmacokinetic mechanism.",
          "key_findings": "HU6, a mitochondrial uncoupler, produced modest but significant reductions in body weight, total fat mass, and visceral fat percentage over 19 weeks versus placebo in obese HFpEF patients (mean age ~64.5 years), without significant changes in peak VO2 or other functional/cardiac biomarkers. Serious adverse events (including one death) were reported but considered unrelated to treatment. No data are provided on age-stratified metabolism or clearance, or on liver/kidney function impacts on HU6 pharmacokinetics.",
          "pmid": "40072462",
          "title": "Novel Controlled Metabolic Accelerator for Obesity-Related HFpEF: The HuMAIN-HFpEF Randomized Clinical Trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "support",
          "confidence": "medium",
          "reasoning": "The abstract explicitly mentions pediatric pharmacological considerations, including age-specific differences in drug clearance and volume of distribution, as important factors when considering tenecteplase use in children. This directly aligns with the proposed mechanism that age-related changes in metabolism and clearance (linked to organ function differences across ages) alter drug handling. Although it does not provide empirical outcome data or directly attribute these differences to liver or kidney function, it clearly supports the concept that age-dependent pharmacokinetics affect drug metabolism/clearance.",
          "key_findings": "The abstract states that: (1) there is very limited experience with tenecteplase in children; (2) changes in fibrinolytic capacity over childhood and pediatric pharmacological considerations, such as age-specific differences in drug clearance and volume of distribution, may impact decisions about thrombolytic therapy; and (3) these age-related pharmacokinetic differences must be considered when transitioning from alteplase to tenecteplase in acute pediatric stroke treatment.",
          "pmid": "37226774",
          "title": "Tenecteplase in Acute Stroke: What About the Children?",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses dietary potassium intake, blood pressure, cardiovascular risk, bone health, and kidney stones, but does not address age-related changes in drug metabolism or clearance, nor liver or kidney function changes in the context of pharmacokinetics. It is focused on nutrient effects and disease outcomes, not pharmacological metabolism mechanisms.",
          "key_findings": "Potassium intake is associated with blood pressure reduction and reduced risk of stroke and coronary heart disease; adequate potassium may protect against age-related bone loss and kidney stones; benefits depend on potassium in foods vs potassium chloride; current Western diets are relatively low in potassium and high in sodium; low potassium-to-sodium ratios are linked to higher cardiovascular disease risk.",
          "pmid": "23674806",
          "title": "Potassium and health.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses prasugrel\u2019s efficacy and bleeding risk, with age-based recommendations (<75 years), but it does not examine or attribute these differences to age-related changes in hepatic or renal drug metabolism or clearance. No pharmacokinetic or organ-function data are presented, so it neither supports nor contradicts the proposed mechanism about age-related metabolic/clearance alterations.",
          "key_findings": "Prasugrel is more potent and consistent than clopidogrel, reduces ischemic events more but increases major bleeding risk, especially in certain subgroups. Recommended ideal use is in patients younger than 75 years and weighing more than 60 kg, with consideration of dose modifications to minimize bleeding. No mention of liver/kidney function changes or age-related pharmacokinetic alterations.",
          "pmid": "22906902",
          "title": "Prasugrel.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract compares bleeding risk between abelacimab and rivaroxaban, including in patients with reduced creatinine clearance, but it does not analyze age-related changes in hepatic or renal function, nor does it examine pharmacokinetics, drug metabolism, or clearance as a function of age. Any mention of dose adjustment based on creatinine clearance is protocol-driven, not an investigation of age-related metabolic changes.",
          "key_findings": "The AZALEA-TIMI 71 trial showed that abelacimab, a factor XI inhibitor, significantly reduced major or clinically relevant nonmajor bleeding compared with rivaroxaban in patients with atrial fibrillation, both with and without concomitant antiplatelet therapy. Rivaroxaban dose was reduced in patients with creatinine clearance \u226450 mL/min, but the study did not assess age-related alterations in drug metabolism or clearance, nor did it relate outcomes specifically to age-related liver or kidney function changes.",
          "pmid": "40546068",
          "title": "Abelacimab Versus Rivaroxaban in Patients With Atrial Fibrillation on Antiplatelet Therapy: A Prespecified Analysis of the AZALEA-TIMI 71 Trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses antithrombotic use in pediatric patients, including mechanisms of action, routes of clearance, and half-lives, but it focuses on children and does not address age-related changes in drug metabolism and clearance due to liver and kidney function across the aging spectrum (e.g., from younger to older adults). Therefore it neither supports nor contradicts the proposed mechanism about age-related alterations in metabolism and clearance.",
          "key_findings": "The abstract states that antithrombotic agents in children have distinct mechanisms of action, clearance routes, half-lives, safety and dosing, and that the manuscript reviews mechanism of action, route of administration, route of clearance and plasma half-life for these agents in children.",
          "pmid": "39168548",
          "title": "Anticoagulation in Pediatric Patients.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses CADASIL pathogenesis in terms of Notch3 mutations, granular osmiophilic material, and vascular smooth muscle cell metabolism, but does not address age-related changes in drug metabolism or clearance, nor liver or kidney function or pharmacokinetics. Therefore it neither supports nor contradicts the proposed pharmacological mechanism.",
          "key_findings": "CADASIL is linked to Notch3 mutations; Notch3 ectodomain accumulates as granular osmiophilic material in vessel walls instead of being cleared after proteolytic cleavage, potentially disrupting smooth muscle cell metabolism. No mention is made of drug metabolism, hepatic or renal clearance, or age-related pharmacokinetic changes.",
          "pmid": "19069156",
          "title": "[CADASIL].",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates short-term renal and glycemic effects and safety of dapagliflozin in youth with type 1 diabetes but does not analyze age-related differences in drug metabolism or clearance, nor does it assess how liver or kidney functional changes with age alter pharmacokinetics or pharmacodynamics.",
          "key_findings": "In 12\u201321-year-old participants with type 1 diabetes, adjunct dapagliflozin (5 mg) for 22 weeks reduced measured GFR, lowered HbA1c, increased time in range, decreased body weight, did not change total daily insulin dose, and had similar adverse events to placebo with one mild DKA case; no age-stratified pharmacokinetic or clearance data, and no evaluation of age-related liver/kidney function effects on drug handling were reported.",
          "pmid": "40481206",
          "title": "Adjunct-to-insulin therapy using SGLT2 inhibitors in youth with type 1 diabetes: a randomized controlled trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract focuses on immunological and inflammatory mechanisms in poststroke dementia, particularly chronic brain inflammation and immune responses. It does not discuss drug metabolism, pharmacokinetics, or age-related changes in liver or kidney function, so it neither supports nor contradicts the proposed mechanism about altered drug clearance with aging.",
          "key_findings": "Stroke increases risk of incident dementia and worsens cognitive trajectory; early poststroke dementia relates to stroke severity and location, while later risk relates to age and traditional dementia risk factors. The review emphasizes a model in which chronic brain inflammation, inefficient clearance of myelin debris, and prolonged innate and adaptive immune responses drive poststroke dementia, potentially influenced by peripheral immune status. No mention is made of pharmacological metabolism, hepatic or renal clearance, or age-related drug handling.",
          "pmid": "31789707",
          "title": "Immunological mechanisms in poststroke dementia.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses complement system activity, neuroinflammation, and age-related neurodegenerative processes in the brain. It does not address hepatic or renal function, systemic drug metabolism, pharmacokinetics, or age-related changes in drug clearance, which are the core of the proposed mechanism.",
          "key_findings": "The paper describes: (1) local production and regulation of complement components in the brain; (2) complement activation and chronic inflammation in age-related diseases like Alzheimer\u2019s disease; (3) roles of complement in neurodegeneration, neuroprotection, and brain development; and (4) potential therapeutic targeting of complement. None of these findings involve age-related changes in liver or kidney function or their impact on drug metabolism/clearance.",
          "pmid": "21546088",
          "title": "Complement in the brain.",
          "analysis_method": "llm"
        }
      ]
    },
    {
      "feature_name": "Baseline NIHSS score",
      "mechanism": {
        "mechanism_type": "biological",
        "description": "Higher NIHSS scores suggest larger areas of initial brain involvement, affecting recovery dynamics and potential ischemia duration.",
        "evidence_level": "moderate"
      },
      "query": "(stroke OR alteplase OR thrombolysis OR \"ischemic stroke\") AND \"Baseline NIHSS score\" AND (\"pathophysiology\" OR \"mechanism\" OR \"causal\" OR \"etiology\" OR \"interaction\") AND (\"involvement\" OR \"potential\" OR \"affecting\") AND (Clinical Trial[PT] OR Review[PT] OR Meta-Analysis[PT])",
      "total_abstracts": 4,
      "support_count": 1,
      "conflict_count": 0,
      "neutral_count": 3,
      "support_percentage": 25.0,
      "conflict_percentage": 0.0,
      "support_ratio": 0.25,
      "abstracts_analyzed": [
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract mentions baseline NIHSS only as an adjustment variable in regression models assessing the effect of intravenous thrombolysis before mechanical thrombectomy. It does not analyze how different NIHSS levels relate to infarct size, ischemia duration, or recovery dynamics, nor does it stratify outcomes by NIHSS or interpret NIHSS as a proxy for initial brain involvement. Therefore, it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "Baseline NIHSS score was included as a covariate in adjusted analyses of the effect of IV thrombolysis on outcomes in the RESILIENT trial, but no results are reported that relate NIHSS to lesion size, duration of ischemia, or recovery patterns. The main findings concern the lack of additional benefit of IV tPA on functional outcome, recanalization, or hemorrhagic transformation when added to mechanical thrombectomy.",
          "pmid": "38182456",
          "title": "The role of intravenous thrombolysis before mechanical Thrombectomy: A subgroup analysis of the RESILIENT trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract reports baseline and 7-day NIHSS scores but does not analyze how higher NIHSS relates to size of initial brain involvement, recovery dynamics, or ischemia duration. NIHSS is used only as a clinical severity/outcome measure, with no mechanistic linkage drawn between higher NIHSS and larger initial brain involvement or temporal aspects of ischemia.",
          "key_findings": "Patients receiving Naoxueshu had worse baseline NIHSS scores (17.2 \u00b1 8.1 vs. 13.7 \u00b1 10.1, p = .039) yet similar 7-day NIHSS scores compared with controls; primary findings focus on reduced 7-day hematoma volume and cerebral edema with Naoxueshu after surgical clot removal in acute intracerebral hemorrhage.",
          "pmid": "33274855",
          "title": "Naoxueshu relieves hematoma after clot removal in acute spontaneous intracerebral hemorrhage.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract mentions baseline NIHSS scores and notes that mild strokes with low NIHSS and small lesion volumes may explain high placebo response, but it does not analyze or quantify any relationship between NIHSS level and extent of initial brain involvement, recovery dynamics, or ischemia duration. NIHSS is used descriptively, not mechanistically, so the specific proposed mechanism is neither supported nor contradicted.",
          "key_findings": "Median baseline NIHSS was 9 (IQR 6\u201314); patients had small core lesions and mismatch volumes, and many had no vessel occlusions. Authors suggest that these mild strokes with low NIHSS and small lesions may have reduced the ability to detect a treatment effect. No explicit assessment of how higher NIHSS relates to lesion size, recovery trajectory, or ischemia duration is provided.",
          "pmid": "19097942",
          "title": "Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study.",
          "analysis_method": "llm"
        },
        {
          "stance": "support",
          "confidence": "medium",
          "reasoning": "The proposed mechanism links higher baseline NIHSS scores to larger initial brain involvement and different recovery dynamics. The abstract shows that posterior circulation strokes have lower baseline NIHSS scores and better unadjusted 3\u2011month outcomes than anterior circulation strokes, but that this outcome difference disappears after adjusting for baseline NIHSS and other factors. This implies that initial stroke severity (as captured by NIHSS) is a key determinant of recovery dynamics across vascular distributions, consistent with the mechanism that NIHSS level (reflecting extent of initial involvement) affects recovery and functional outcome.",
          "key_findings": "1) Mean baseline NIHSS was lower in posterior circulation (PC 6.1) than anterior circulation (AC 9.5; p < 0.001), indicating less severe initial involvement in PC strokes.\n2) On univariate analysis, favorable 3\u2011month outcome was more common in PC than AC patients in both placebo and heparinoid groups.\n3) On multivariate analysis controlling for baseline NIHSS (and gender, prior stroke), the outcome difference between PC and AC strokes disappeared, indicating that baseline NIHSS is a major driver of outcome.\n4) These results support the idea that the degree of initial neurological deficit (NIHSS level), which reflects initial brain involvement, strongly influences recovery dynamics and long\u2011term outcome.",
          "pmid": "11385210",
          "title": "Differences between anterior and posterior circulation stroke in TOAST.",
          "analysis_method": "llm"
        }
      ]
    },
    {
      "feature_name": "Baseline NIHSS score",
      "mechanism": {
        "mechanism_type": "statistical",
        "description": "The NIHSS score is a robust predictor of post-treatment outcomes, informative of both immediate and long-term trajectories.",
        "evidence_level": "strong"
      },
      "query": "(stroke OR alteplase OR thrombolysis OR \"ischemic stroke\") AND \"Baseline NIHSS score\" AND (\"independent predictor\" OR \"confounding\" OR \"interaction effect\") AND (\"trajectories\" OR \"informative\" OR \"immediate\") AND (Clinical Trial[PT] OR Review[PT] OR Meta-Analysis[PT])",
      "total_abstracts": 0,
      "support_count": 0,
      "conflict_count": 0,
      "neutral_count": 0,
      "abstracts_analyzed": []
    },
    {
      "feature_name": "Baseline NIHSS score",
      "mechanism": {
        "mechanism_type": "pharmacological",
        "description": "Higher NIHSS typically indicates larger or more complex thrombi, which may be less responsive to standard alteplase treatment.",
        "evidence_level": "moderate"
      },
      "query": "(stroke OR alteplase OR thrombolysis OR \"ischemic stroke\") AND \"Baseline NIHSS score\" AND (\"pharmacokinetics\" OR \"pharmacodynamics\" OR \"dose-response\" OR \"clearance\") AND (\"responsive\" OR \"indicates\" OR \"alteplase\") AND (Clinical Trial[PT] OR Review[PT] OR Meta-Analysis[PT])",
      "total_abstracts": 0,
      "support_count": 0,
      "conflict_count": 0,
      "neutral_count": 0,
      "abstracts_analyzed": []
    },
    {
      "feature_name": "Time to treatment",
      "mechanism": {
        "mechanism_type": "pharmacological",
        "description": "Administering alteplase early maximizes thrombolysis potential before irreversible damage.",
        "evidence_level": "strong"
      },
      "query": "(stroke OR alteplase OR thrombolysis OR \"ischemic stroke\") AND \"Time to treatment\" AND (\"pharmacokinetics\" OR \"pharmacodynamics\" OR \"dose-response\" OR \"clearance\") AND (\"administering\" OR \"thrombolysis\" OR \"irreversible\") AND (Clinical Trial[PT] OR Review[PT] OR Meta-Analysis[PT])",
      "total_abstracts": 6,
      "support_count": 0,
      "conflict_count": 0,
      "neutral_count": 6,
      "support_percentage": 0.0,
      "conflict_percentage": 0.0,
      "support_ratio": 0.0,
      "abstracts_analyzed": [
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract compares tenecteplase with alteplase and discusses recanalization, outcomes, dosing, and time windows, but it does not specifically evaluate or present data on the effect of *early* alteplase administration on maximizing thrombolysis before irreversible damage. Timing of alteplase relative to stroke onset and its mechanistic impact is not directly addressed.",
          "key_findings": "Tenecteplase has higher fibrin specificity and longer half-life than alteplase and can be given as a single bolus. Meta-analyses of randomized trials (1585 patients) suggest tenecteplase is superior to alteplase for recanalization of large vessel occlusions and noninferior for 3\u2011month disability-free outcome without higher rates of symptomatic intracranial hemorrhage or mortality. Doses of 0.25 and 0.4 mg/kg have been tested, with no advantage of the higher dose. Guidelines list IV tenecteplase as a second-tier option, 0.25 mg/kg favored for large vessel occlusion. Ongoing phase 3 trials aim to clarify comparative risks/benefits and efficacy in extended time windows (>4.5 hours, wake-up stroke, and with thrombectomy).",
          "pmid": "33045929",
          "title": "Tenecteplase Thrombolysis for Acute Ischemic Stroke.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The proposed mechanism concerns the benefit of administering alteplase early, before irreversible damage occurs. This trial specifically studies patients with unknown time of onset selected by MRI (DWI+/FLAIR\u2013), not timing from stroke onset per se, and compares low-dose alteplase vs standard care. It reports no difference in functional outcome but is underpowered and does not directly test or quantify how earlier administration relative to onset affects thrombolysis effectiveness or tissue fate. Thus it neither validates nor refutes the timing-based mechanistic claim.",
          "key_findings": "In MRI-selected ischemic stroke with unknown onset (including wake-up strokes), alteplase 0.6 mg/kg vs standard medical treatment showed similar 90-day favorable outcome (mRS 0\u20131: 47.1% vs 48.3%; RR 0.97, 95% CI 0.68\u20131.41) and comparable symptomatic intracranial hemorrhage and mortality, with the trial stopped early and considered inconclusive. The study does not analyze outcomes as a function of treatment time from stroke onset or explicitly address maximizing thrombolysis before irreversible damage.",
          "pmid": "32248771",
          "title": "Thrombolysis With Alteplase at 0.6 mg/kg for Stroke With Unknown Time of Onset: A Randomized Controlled Trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates natalizumab in acute ischemic stroke and reports no benefit and possible worse functional outcomes versus placebo. It does not study alteplase or the timing of alteplase administration, nor does it assess how early thrombolysis affects irreversible damage. Thus it provides no direct evidence for or against the proposed alteplase-specific, time-dependent thrombolysis mechanism.",
          "key_findings": "In AIS patients treated within \u226424 hours, natalizumab (300 or 600 mg IV) led to a lower likelihood of excellent outcome at 90 days compared with placebo (OR 0.60; 95% CI 0.39\u20130.93), with no effect modification by time to treatment or use of thrombolysis/thrombectomy. Safety outcomes (AEs, SAEs, deaths) were similar across groups.",
          "pmid": "32591475",
          "title": "Natalizumab in acute ischemic stroke (ACTION II): A randomized, placebo-controlled trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract compares TNK-tPA bolus dosing with front\u2011loaded alteplase in acute MI and focuses on reperfusion rates, dose\u2013response, and bleeding risk. It does not analyze or compare outcomes based on how early alteplase is given within the 12\u2011hour window, nor does it address the relationship between timing of alteplase administration and prevention of irreversible damage. Thus it neither supports nor contradicts the specific mechanism that earlier alteplase maximizes thrombolysis before irreversible injury.",
          "key_findings": "Patients with acute ST-elevation MI within 12 hours were randomized to different TNK-tPA doses versus front-loaded alteplase; TNK-tPA 40 mg achieved similar 90\u2011minute TIMI grade 3 flow compared with alteplase; higher TNK-tPA doses showed better reperfusion but more bleeding; reduced heparin dosing improved safety. Timing within the 12\u2011hour window and its impact on irreversible damage were not evaluated.",
          "pmid": "9860780",
          "title": "TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract concerns aspirin use, intolerance, bleeding, and discontinuation in post\u2013acute coronary syndrome patients. It does not involve alteplase, thrombolysis, timing of thrombolytic administration, or mechanisms related to maximizing thrombolysis before irreversible damage. Therefore, it neither supports nor contradicts the proposed alteplase mechanism.",
          "key_findings": "In 5337 post-acute coronary syndrome patients randomized to aspirin, about 18% discontinued study aspirin, with factors such as black race, recurrent ischemia, hypertension, COPD, lighter weight, shorter time to treatment, and certain concomitant medications associated with early discontinuation. Bleeding occurred in 12.6% of patients, but only 1.0% discontinued aspirin due to bleeding. These data relate to aspirin adherence and bleeding risk, not to alteplase or timing of thrombolysis.",
          "pmid": "15087598",
          "title": "Aspirin use post-acute coronary syndromes: intolerance, bleeding and discontinuation.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The study compares procoagulant effects (thrombin generation via TAT levels) of different thrombolytics (streptokinase, rt-PA, TNK-t-PA) given within 6 hours of MI onset, but it does not evaluate how earlier vs later alteplase (rt-PA) administration affects the extent of thrombolysis or irreversible tissue damage. The proposed mechanism concerns timing-dependent efficacy of alteplase in maximizing thrombolysis before irreversible injury, which is not addressed here.",
          "key_findings": "In 29 acute MI patients treated within 6 hours, streptokinase and rt-PA infusions significantly increased TAT levels at 2 hours (26 \u00b1 6 and 21 \u00b1 4 \u00b5g/L, respectively, vs baseline ~9 \u00b5g/L), indicating a procoagulant effect, whereas TNK-t-PA bolus did not increase TAT and was similar to non-thrombolysis controls, suggesting TNK-t-PA lacks the procoagulant effect seen with streptokinase and rt-PA.",
          "pmid": "9922587",
          "title": "[The absence of a procoagulant effect after TNK-t-PA: a comparison with streptokinase and rt-PA].",
          "analysis_method": "llm"
        }
      ]
    },
    {
      "feature_name": "Time to treatment",
      "mechanism": {
        "mechanism_type": "biological",
        "description": "Early treatment improves penumbra salvage, enhancing recovery potential and functional outcomes.",
        "evidence_level": "strong"
      },
      "query": "(stroke OR alteplase OR thrombolysis OR \"ischemic stroke\") AND \"Time to treatment\" AND (\"pathophysiology\" OR \"mechanism\" OR \"causal\" OR \"etiology\" OR \"interaction\") AND (\"functional\" OR \"enhancing\" OR \"potential\") AND (Clinical Trial[PT] OR Review[PT] OR Meta-Analysis[PT])",
      "total_abstracts": 20,
      "support_count": 6,
      "conflict_count": 5,
      "neutral_count": 9,
      "support_percentage": 30.0,
      "conflict_percentage": 25.0,
      "support_ratio": 0.3,
      "abstracts_analyzed": [
        {
          "stance": "support",
          "confidence": "high",
          "reasoning": "The abstract shows that earlier administration of IVT (before thrombectomy) is associated with better 90\u2011day functional outcomes, with benefit declining as onset-to-treatment time increases and becoming non-significant after ~2 hours 20 minutes. This temporal dependence is consistent with the concept that earlier reperfusion salvages more penumbral tissue, thereby enhancing recovery potential and functional outcomes, which directly aligns with the proposed mechanism.",
          "key_findings": "In 2313 anterior-circulation LVO patients eligible for IVT and thrombectomy, a significant interaction was found between onset-to-IVT time and functional benefit of IVT plus thrombectomy vs thrombectomy alone (ratio of adjusted common OR per 1\u2011hour delay, 0.84 [95% CI, 0.72\u20130.97], P=.02). The adjusted common OR for a 1-step mRS improvement was 1.49 at 1 hour, 1.25 at 2 hours, and 1.04 at 3 hours, indicating diminishing benefit with delay. Predicted absolute risk difference for mRS 0\u20132 was 9% at 1 hour, 5% at 2 hours, and 1% at 3 hours. After 2 hours 20 minutes, the benefit was no longer statistically significant, and the point estimate crossed the null at 3 hours 14 minutes. These results indicate that earlier treatment leads to better functional outcomes, consistent with improved salvage of at-risk brain tissue.",
          "pmid": "38324409",
          "title": "Time to Treatment With Intravenous Thrombolysis Before Thrombectomy and Functional Outcomes in Acute Ischemic Stroke: A Meta-Analysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "support",
          "confidence": "medium",
          "reasoning": "The trial shows that in carefully selected patients treated 6\u201324 hours after stroke onset, endovascular thrombectomy leads to markedly better 90\u2011day functional outcomes than standard care, consistent with salvage of at\u2011risk but not yet infarcted tissue (penumbra) even at later time points. This supports the broader biological mechanism that earlier or timely reperfusion to rescue viable tissue improves recovery potential and functional outcomes, although the study specifically examines late rather than ultra\u2011early treatment and does not directly measure penumbra salvage.",
          "key_findings": "Patients 6\u201324 hours from last known well with intracranial ICA or proximal MCA occlusion and a deficit\u2013infarct mismatch randomized to thrombectomy plus standard care had a higher mean utility\u2011weighted modified Rankin score at 90 days (5.5 vs 3.4; adjusted difference 2.0; 95% credible interval 1.1\u20133.0; posterior probability of superiority >0.999) and higher functional independence (49% vs 13%; adjusted difference 33 percentage points; 95% credible interval 24\u201344; posterior probability of superiority >0.999) compared with standard care alone, without increased mortality or symptomatic intracranial hemorrhage. These findings indicate that reperfusion therapy in the presence of salvageable tissue substantially improves functional outcome, aligning with the concept that treatment that preserves at\u2011risk tissue enhances recovery potential.",
          "pmid": "29129157",
          "title": "Thrombectomy 6 to 24 Hours after Stroke with a Mismatch between Deficit and Infarct.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "medium",
          "reasoning": "The proposed mechanism concerns how earlier treatment improves penumbra salvage and thereby functional outcomes. This trial compares two reperfusion strategies (thrombectomy alone vs. thrombectomy plus IV alteplase within 4.5 hours) and finds noninferior 90\u2011day functional outcomes despite lower successful reperfusion rates in the thrombectomy-alone group. However, the study does not directly analyze timing-dependent penumbra salvage or quantify salvageable tissue; it only assesses outcomes of two treatment strategies within a fixed time window and a defined noninferiority margin. Thus it neither directly tests nor clearly supports or refutes the specific mechanism that earlier treatment improves penumbral salvage and functional recovery.",
          "key_findings": "Patients with large-vessel anterior circulation stroke were randomized to thrombectomy alone vs. thrombectomy plus IV alteplase given within 4.5 hours. Thrombectomy alone was noninferior for 90\u2011day modified Rankin Scale distribution (adjusted common OR 1.07; 95% CI 0.81\u20131.40). Reperfusion before thrombectomy (2.4% vs. 7.0%) and overall successful reperfusion (79.4% vs. 84.5%) were lower in the thrombectomy-alone group, but mortality and functional outcomes were similar. The trial did not compare earlier vs. later treatment times or directly measure penumbra salvage.",
          "pmid": "32374959",
          "title": "Endovascular Thrombectomy with or without Intravenous Alteplase in Acute Stroke.",
          "analysis_method": "llm"
        },
        {
          "stance": "conflict",
          "confidence": "medium",
          "reasoning": "The mechanism claims that earlier treatment improves salvage and functional outcomes in general. This trial tested very early, prehospital blood-pressure reduction (within ~1 hour of onset) and found no overall functional benefit in an undifferentiated acute stroke population, and worse functional outcomes in ischemic stroke. Although benefit was seen in hemorrhagic stroke, the mechanism as stated is broad and not stroke-type\u2013specific, so the net evidence conflicts with a general claim that early treatment (here, early BP lowering) improves functional outcomes.",
          "key_findings": "\u2022 Patients with suspected acute stroke and elevated systolic blood pressure were randomized in the ambulance within 2 hours of symptom onset to intensive BP lowering vs usual care.\n\u2022 Median onset-to-randomization time was 61 minutes; prehospital BP reduction achieved lower systolic BP on hospital arrival (159 vs 170 mm Hg).\n\u2022 Overall, there was no difference in 90\u2011day functional outcome (mRS) between intensive BP lowering and usual care (common OR 1.00, 95% CI 0.87\u20131.15).\n\u2022 In hemorrhagic stroke, prehospital BP reduction decreased odds of poor functional outcome (OR 0.75, 95% CI 0.60\u20130.92).\n\u2022 In ischemic (cerebral ischemia) stroke, prehospital BP reduction increased odds of poor functional outcome (OR 1.30, 95% CI 1.06\u20131.60).\n\u2022 Serious adverse events were similar between groups.",
          "pmid": "38752650",
          "title": "Intensive Ambulance-Delivered Blood-Pressure Reduction in Hyperacute Stroke.",
          "analysis_method": "llm"
        },
        {
          "stance": "conflict",
          "confidence": "medium",
          "reasoning": "The proposed mechanism claims that early treatment improves penumbra salvage and thus functional outcomes. In this trial, patients with minor, nondisabling ischemic stroke treated very early (within 3 hours) with alteplase did not have better 90-day functional outcomes than those treated with aspirin, despite the time window being favorable for penumbra salvage. Instead, there was no functional benefit and an increased risk of symptomatic intracranial hemorrhage, which conflicts with the idea that early reperfusion treatment in this population enhances recovery potential and functional outcome. However, confidence is limited by the trial\u2019s early termination and restricted population (minor, nondisabling strokes).",
          "key_findings": "Adults with minor, nondisabling acute ischemic stroke (NIHSS 0\u20135) treated within 3 hours were randomized to alteplase vs aspirin. Favorable functional outcome (mRS 0\u20131 at 90 days) occurred in 78.2% of the alteplase group vs 81.5% of the aspirin group (adjusted risk difference \u22121.1%; 95% CI, \u22129.4% to 7.3%), indicating no improvement in functional outcome with early alteplase. Symptomatic intracranial hemorrhage occurred in 3.2% of alteplase-treated patients vs 0% in the aspirin group. The authors conclude that alteplase did not increase the likelihood of favorable functional outcome in this early-treated, minor-nondisabling stroke population, though early termination limits definitiveness.",
          "pmid": "29998337",
          "title": "Effect of Alteplase vs Aspirin on Functional Outcome for Patients With Acute Ischemic Stroke and Minor Nondisabling Neurologic Deficits: The PRISMS Randomized Clinical Trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The trial compares endovascular therapy versus standard medical care within 6 hours for basilar artery occlusion but does not analyze how earlier versus later treatment within that window affects penumbra salvage or functional outcomes. No imaging, penumbra metrics, or time-to-treatment gradient analyses are presented that would directly address the mechanism that early treatment improves penumbra salvage and recovery potential.",
          "key_findings": "Patients with basilar-artery occlusion were randomized within 6 hours to endovascular therapy or medical care. Endovascular treatment started at a median of 4.4 hours. Favorable functional outcome (mRS 0\u20133 at 90 days) occurred in 44.2% vs 37.7% (RR 1.18, 95% CI 0.92\u20131.50), with no statistically significant difference. Symptomatic intracranial hemorrhage was higher in the endovascular group (4.5% vs 0.7%), and mortality was slightly lower (38.3% vs 43.2%; RR 0.87, 95% CI 0.68\u20131.12). The study does not examine outcome as a function of earlier versus later treatment or demonstrate penumbra salvage.",
          "pmid": "34010530",
          "title": "Endovascular Therapy for Stroke Due to Basilar-Artery Occlusion.",
          "analysis_method": "llm"
        },
        {
          "stance": "conflict",
          "confidence": "high",
          "reasoning": "The proposed mechanism states that earlier treatment improves salvage of vulnerable tissue and thus functional outcomes. This trial tested very early (within 2 hours) administration of tranexamic acid after traumatic brain injury and explicitly measured long-term functional neurologic outcomes. Early treatment did not significantly improve 6\u2011month functional outcomes, mortality, disability scores, or radiographic hemorrhage progression compared with placebo. This directly contradicts the expectation that early pharmacologic intervention in this context enhances recovery potential and functional outcome.",
          "key_findings": "In a multicenter RCT of 966 moderate/severe TBI patients treated within 2 hours of injury, out-of-hospital tranexamic acid (bolus\u00b1maintenance) vs placebo resulted in: (1) similar rates of favorable 6\u2011month neurologic outcome (65% vs 62%; P=.16), (2) no significant difference in 28\u2011day mortality (14% vs 17%; P=.26), (3) no significant difference in 6\u2011month Disability Rating Scale scores (6.8 vs 7.6; P=.29), and (4) no significant difference in progression of intracranial hemorrhage (16% vs 20%; P=.16). Thus, early treatment did not improve functional outcomes.",
          "pmid": "32897344",
          "title": "Effect of Out-of-Hospital Tranexamic Acid vs Placebo on 6-Month Functional Neurologic Outcomes in Patients With Moderate or Severe Traumatic Brain Injury.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses tPA use within 3 hours of cerebral vessel occlusion and newer clot retrieval methods, but it does not present data or explicit claims about penumbra salvage, recovery potential, or functional outcomes as a function of earlier versus later treatment. It is descriptive and forward-looking rather than mechanistic or outcome-focused regarding treatment timing.",
          "key_findings": "tPA was approved for recent (<3 h) cerebral vessel occlusion; advances in stent retriever clot retrieval used with tPA offer optimism for ischemic stroke; there is a need for therapies to minimize hypoxic damage and protect compromised cells; a range of approaches (hypothermia, cell therapy, neuroprotection) are under clinical investigation. No specific evidence is provided about how early treatment affects penumbra salvage or functional recovery.",
          "pmid": "28674985",
          "title": "Stroke: Basic and Clinical.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "medium",
          "reasoning": "The abstract mentions that time to treatment is likely to be very important for ICH as it is for ischemic stroke, but this is presented as an expectation, not as demonstrated evidence of improved penumbra salvage or better functional outcomes. No data or results are provided that show early treatment improves salvage of at-risk tissue or outcomes, so it does not directly support or refute the proposed mechanism.",
          "key_findings": "The abstract states that: (1) no current therapeutic modality has clearly shown beneficial long-term outcome for ICH in small randomized trials; (2) new therapeutic strategies are being identified; and (3) time to treatment is likely to be very important, by analogy to ischemic stroke. However, it does not present empirical evidence linking early treatment to improved penumbra salvage or functional recovery.",
          "pmid": "10757834",
          "title": "Intracerebral hemorrhage.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "medium",
          "reasoning": "The abstract discusses the concept and trials of early rehabilitation (within 7 days) and suggests that early mobility and other therapies are generally well tolerated, but it does not present concrete outcome data showing that earlier treatment improves penumbra salvage or definitively enhances functional outcomes. It references the AVERT trial as indicating a need for caution <24 hours, but without detailed results. Overall, it frames early rehabilitation as promising and biologically plausible rather than providing direct, strong evidence for improved recovery attributable to early intervention.",
          "key_findings": "1) Early rehabilitation (mobilization, aphasia, dysphagia, upper limb treatment) within 7 days of stroke is being tested, but trials in this window are few. 2) Early mobility training and mobilization appear well tolerated, with few reasons to delay some rehabilitation within the first week. 3) The AVERT trial suggests that a cautious approach is needed immediately (<24 h) after stroke. 4) The review emphasizes that early rehabilitation may optimize recovery potential in a critical window for repair, but presents this largely as rationale and ongoing research rather than definitive outcome evidence.",
          "pmid": "27845945",
          "title": "Early rehabilitation after stroke.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "medium",
          "reasoning": "The proposed mechanism concerns earlier treatment improving penumbra salvage and thereby functional outcomes in general. This abstract evaluates whether the *relative* effect of adding IVT to MT is modified by onset-to-needle or door-to-needle times within an RCT, and finds no significant interaction for functional independence, with only exploratory signals in secondary outcomes for shorter in-hospital delays. It does not directly measure penumbra salvage, nor does it robustly demonstrate that earlier treatment improves outcomes overall; instead, it tests whether time modifies the incremental benefit of bridging IVT. Thus it neither clearly supports nor clearly contradicts the broader early-treatment penumbra-salvage mechanism.",
          "key_findings": "In 408 patients randomized to IVT+MT vs MT alone, there was no significant interaction between onset-to-needle time and treatment assignment for functional independence at 3 months (aOR 0.76, 95% CI 0.45\u20131.30) or safety/recanalization outcomes. Similarly, no significant interaction was found between door-to-needle time and treatment assignment for dichotomized functional outcome (aOR 0.48, 95% CI 0.14\u20131.62). Exploratory analyses of secondary outcomes (mRS shift and mortality) suggested a potentially greater benefit of IVT when in-hospital delays were short, but the study was underpowered and these findings were not definitive.",
          "pmid": "35902234",
          "title": "Time to treatment with bridging intravenous alteplase before endovascular treatment:subanalysis of the randomized controlled SWIFT-DIRECT trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The proposed mechanism concerns earlier treatment improving penumbra salvage and functional outcomes. This meta-analysis compares organizational models of tPA delivery (drip-and-stay vs drip-and-ship vs hub) and shows non-inferior outcomes across models, but it does not report or compare treatment-onset times, penumbra salvage metrics, or time-dependent outcome differences. Thus it neither directly supports nor contradicts the specific mechanistic claim that earlier treatment enhances penumbra salvage.",
          "key_findings": "Among 4,164 acute ischemic stroke patients treated with IV tPA across 10 studies, drip-and-stay care was non-inferior to drip-and-ship or hub models with respect to functional independence (mRS 0\u20131; RR 1.09, 95% CI 0.98\u20131.22, p=0.123), symptomatic intracranial hemorrhage (RR 0.98, 95% CI 0.64\u20131.51, p=0.942), and 90-day mortality (RR 0.98, 95% CI 0.73\u20131.32, p=0.911). No significant heterogeneity was observed. The abstract does not assess treatment timing or penumbra salvage directly.",
          "pmid": "33540336",
          "title": "Efficacy and Safety of the Telestroke Drip-And-Stay Model: A Systematic Review and Meta-Analysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "support",
          "confidence": "medium",
          "reasoning": "The mechanism states that earlier treatment improves penumbra salvage and thereby functional outcomes. This meta-analysis shows that, in perfusion-mismatch\u2013selected patients treated 4.5\u20139 hours or wake-up, reperfusion (i.e., salvage of at-risk tissue) is strongly associated with better functional outcome across all time strata. Although the study does not demonstrate a gradient of benefit with earlier versus later times (no reperfusion\u00d7time interaction), it does directly link penumbra salvage (reperfusion) to improved recovery and functional outcomes, which is a core element of the proposed mechanism.",
          "key_findings": "1) Reperfusion, defined as >90% reduction in perfusion lesion volume at 24\u201372 hours, was associated with substantially improved 90-day functional outcome (common OR 7.7, 95% CI 4.6\u201312.8; P<.001). 2) This association between reperfusion and better functional outcome was present in each time stratum (4.5\u20136 h, 6\u20139 h, and wake-up strokes). 3) There was no evidence that time from onset to randomization modified the benefit of reperfusion (P for interaction = .63), indicating consistent benefit of penumbral salvage across the extended time window. 4) Symptomatic hemorrhage risk did not differ across time strata in alteplase-treated patients, supporting the safety of seeking reperfusion\u2014and thus penumbra salvage\u2014throughout 4.5\u20139 hours and wake-up periods.",
          "pmid": "33137171",
          "title": "Association of Reperfusion After Thrombolysis With Clinical Outcome Across the 4.5- to 9-Hours and Wake-up Stroke Time Window: A Meta-Analysis of the EXTEND and EPITHET Randomized Clinical Trials.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "medium",
          "reasoning": "The mechanism concerns earlier treatment improving penumbra salvage and thereby functional outcomes. This meta-analysis compares endovascular treatment versus general treatment and identifies subgroups (including maximum delay for intervention >5 hours) associated with better outcomes, but it does not analyze onset\u2011to\u2011treatment time as a continuous or categorical early-vs-late variable, nor does it evaluate penumbra salvage directly. The finding that patients with a maximum delay >5 hours can still benefit from EVT relates to treatment window and outcomes, but it neither directly tests nor specifically supports the claim that earlier treatment enhances penumbra salvage and functional recovery.",
          "key_findings": "Endovascular treatment (EVT) vs general treatment in acute ischemic stroke showed improved 90\u2011day functional outcomes (mRS 0\u20131 OR 1.68; mRS 0\u20132 OR 1.78), reduced all\u2011cause mortality (OR 0.82), and higher risk of asymptomatic intracerebral hemorrhage (OR 1.43). Subgroup analysis suggested that age <70, NIHSS \u226520, and maximum delay for intervention >5 hours were associated with improved outcomes following EVT.",
          "pmid": "32443338",
          "title": "Endovascular treatment or general treatment: how should acute ischemic stroke patients choose to benefit from them the most?: A systematic review and meta-analysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "medium",
          "reasoning": "The abstract clearly states that earlier thrombolytic treatment (<3h IV, <6h intra-arterial) is one of the most important predictors of clinical success and improves 90-day outcomes and reduces hemorrhage. However, it does not present data or explicit mechanistic evidence that this benefit is mediated specifically via penumbra salvage. Penumbra and imaging-based penumbra identification are mentioned as concepts that may improve selection, but no direct causal link between earlier treatment, penumbra salvage, and enhanced recovery potential is demonstrated in this document.",
          "key_findings": "1) Time to treatment is described as one of the most important predictors of clinical success, with early treatment (<3 hours for IV tPA and <6 hours for intra-arterial thrombolysis) associated with significant improvement in 90-day clinical outcome and reduced cerebral hemorrhage.\n2) The text notes that improved imaging to identify the ischemic penumbra and distinguish it from irreversibly infarcted tissue may better select patients for therapy than symptom duration.\n3) It emphasizes that outcome is influenced by multiple interrelated variables including collateral circulation, ischemic penumbra, lesion location and extent, time to treatment, and hemorrhagic conversion, but does not provide direct evidence that early treatment benefits are specifically due to penumbra salvage.",
          "pmid": "12869717",
          "title": "Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke.",
          "analysis_method": "llm"
        },
        {
          "stance": "support",
          "confidence": "high",
          "reasoning": "The abstract explicitly states that intravenous t-PA improves outcomes when administered within 4.5 hours of symptom onset and that mechanical thrombectomy eligibility is constrained by patients presenting early enough (within 6 hours, or selected 6\u201324 hours). This aligns with the proposed mechanism that earlier treatment in acute ischemic stroke leads to better recovery potential and functional outcomes via improved salvage of at-risk brain tissue (penumbra), even though the term 'penumbra' is not used explicitly.",
          "key_findings": "1) Intravenous tissue-type plasminogen activator (t-PA), when administered within 4.5 hours of stroke symptom onset, improves outcome in stroke patients. 2) Mechanical thrombectomy is the preferred treatment for large-artery anterior circulation occlusion, but only patients who present sufficiently early (within 6 hours, or selected 6\u201324 hours) can undergo the procedure. 3) The discussion centers on enhancing fibrinolytic therapy to improve efficacy and safety, implicitly relying on the time-sensitive nature of reperfusion therapy effectiveness.",
          "pmid": "29953716",
          "title": "Fibrinolysis: strategies to enhance the treatment of acute ischemic stroke.",
          "analysis_method": "llm"
        },
        {
          "stance": "support",
          "confidence": "high",
          "reasoning": "The abstract explicitly shows that, among patients given alteplase, faster time to treatment increases the proportion achieving an excellent functional outcome (mRS 0\u20131) and that within 4.5 hours the absolute gain in good outcome outweighs the increased risk of fatal intracerebral hemorrhage and mortality. This directly supports the mechanism that earlier treatment enhances recovery potential and functional outcomes (consistent with better penumbra salvage), even though penumbral biology is not explicitly measured.",
          "key_findings": "1) Alteplase improves the odds of a good outcome when delivered within 4.5 hours of acute ischemic stroke. 2) For patients treated within 4.5 hours, the absolute increase in excellent outcome (mRS 0\u20131) of 6.8% exceeds the absolute increase in risk of fatal intracerebral hemorrhage (2.2%) and any death within 90 days (0.9%). 3) Among patients given alteplase, net outcome is predicted by time to treatment, with faster time increasing the proportion achieving an excellent outcome. 4) Early treatment is especially important for patients with severe stroke, linking timeliness of therapy with functional recovery despite higher hemorrhage risk.",
          "pmid": "27289487",
          "title": "Risk of intracerebral haemorrhage with alteplase after acute ischaemic stroke: a secondary analysis of an individual patient data meta-analysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "support",
          "confidence": "high",
          "reasoning": "The mechanism posits that earlier effective treatment improves salvage of ischemic but viable tissue (penumbra), thereby enhancing recovery and functional outcomes. This abstract shows that early reperfusion (pre-EVT, plausibly reflecting better penumbral salvage) is associated with better functional outcome, and that intravenous alteplase increases the likelihood of such early reperfusion, particularly when EVT is delayed. Thus, it directly supports the idea that earlier restoration of blood flow improves functional outcomes via enhanced tissue salvage.",
          "key_findings": "1) Early reperfusion before endovascular treatment (eTICI \u22652a) occurred in 15% of patients and was associated with better functional outcome (mRS 0\u20132: 54% vs 34%; adjusted OR 1.92, 95% CI 1.15\u20133.21).\n2) Intravenous alteplase was independently associated with higher rates of early reperfusion (19% vs 10%; adjusted OR 2.06, 95% CI 1.27\u20133.33).\n3) The effect of alteplase on early reperfusion was modified by time from randomization to groin puncture: no clear benefit when \u226433 minutes (aOR 1.06, 95% CI 0.53\u20132.10) but strong benefit when >33 minutes (aOR 4.07, 95% CI 1.86\u20138.86), implying that earlier pharmacologic reperfusion during EVT delay improves outcomes, consistent with enhanced salvage of at-risk tissue.",
          "pmid": "35240861",
          "title": "Association of Intravenous Alteplase, Early Reperfusion, and Clinical Outcome in Patients With Large Vessel Occlusion Stroke: Post Hoc Analysis of the Randomized DIRECT-MT Trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "conflict",
          "confidence": "medium",
          "reasoning": "The proposed mechanism claims that earlier treatment improves functional outcomes by better salvaging penumbra. In this trial, earlier initiation of antihypertensive treatment (within 24\u201348 hours) did not improve, and in some patients without prior hypertension actually worsened, functional outcomes at 90 days compared with delayed treatment. This directly opposes the general assertion that earlier treatment (at least for blood pressure lowering in this time window) enhances recovery potential and functional outcome.",
          "key_findings": "In 4810 patients with acute ischemic stroke randomized to early vs delayed antihypertensive therapy: (1) The primary outcome (death or functional dependency, mRS \u22653 at 90 days) did not differ between early and delayed groups regardless of hypertension history (OR 1.11 [0.91\u20131.36] with hypertension; 1.38 [0.92\u20132.08] without hypertension). (2) Ordinal analysis showed early treatment was associated with higher (worse) mRS scores in patients without prior hypertension (OR 1.35 [1.01\u20131.82]) and no benefit in those with hypertension (OR 0.95 [0.82\u20131.10]). (3) Authors conclude that early antihypertensive treatment did not reduce death or dependency and worsened functional outcomes in non-hypertensive patients.",
          "pmid": "39807580",
          "title": "Early Versus Delayed Antihypertensive Treatment After Acute Ischemic Stroke by Hypertension History.",
          "analysis_method": "llm"
        },
        {
          "stance": "conflict",
          "confidence": "medium",
          "reasoning": "The proposed mechanism asserts that earlier treatment improves salvage and functional outcomes. In this study, earlier initiation of antihypertensive therapy (vs delaying to day 8) in acute ischemic stroke patients with single subcortical infarction and parent artery disease stenosis was associated with worse functional outcomes (higher dependency/death at 90 days), and no benefit in those without stenosis. This directly contradicts the general premise that earlier treatment (here, blood pressure lowering) enhances recovery and outcomes, at least for this intervention and stroke subtype.",
          "key_findings": "Among patients with single subcortical infarction (SSI), early vs delayed antihypertensive treatment showed: (1) no overall benefit in functional dependency or death at 90 days (8.8% vs 7.1%; OR 1.25, 95% CI 0.79-1.99); (2) in SSI with parent artery disease stenosis, early treatment increased risk of dependency/death (23.4% vs 7.7%; OR 3.67, 95% CI 1.14-11.86); (3) in SSI without stenosis, no difference (6.6% vs 7.1%; OR 0.93, 95% CI 0.55-1.57). These findings indicate that earlier antihypertensive intervention did not improve and in a subgroup worsened functional outcomes, conflicting with the notion that earlier treatment generally improves recovery potential and outcomes.",
          "pmid": "39212990",
          "title": "Early vs Delayed Antihypertensive Treatment in Acute Single Subcortical Infarction: A Secondary Analysis of the CATIS-2 Randomized Clinical Trial.",
          "analysis_method": "llm"
        }
      ]
    },
    {
      "feature_name": "Time to treatment",
      "mechanism": {
        "mechanism_type": "statistical",
        "description": "Rapid treatment is crucial due to the exponential nature of neuronal deterioration during ischemia.",
        "evidence_level": "strong"
      },
      "query": "(stroke OR alteplase OR thrombolysis OR \"ischemic stroke\") AND \"Time to treatment\" AND (\"independent predictor\" OR \"confounding\" OR \"interaction effect\") AND (\"deterioration\" OR \"exponential\" OR \"treatment\") AND (Clinical Trial[PT] OR Review[PT] OR Meta-Analysis[PT])",
      "total_abstracts": 15,
      "support_count": 1,
      "conflict_count": 1,
      "neutral_count": 13,
      "support_percentage": 6.666666666666667,
      "conflict_percentage": 6.666666666666667,
      "support_ratio": 0.06666666666666667,
      "abstracts_analyzed": [
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract focuses on associations between pre-stroke physical activity and admission stroke severity, and speculates on mechanisms including reduced risk factors, smaller infarcts, distal occlusions, and shorter time-to-treatment. However, it does not analyze or provide data on the temporal dynamics of neuronal deterioration during ischemia, nor does it test or quantify the importance of rapid treatment specifically due to exponential neuronal loss. Thus it neither supports nor contradicts the proposed statistical mechanism about exponential deterioration and the criticality of rapid treatment.",
          "key_findings": "Pre-stroke physical activity is often associated with milder admission stroke severity; mechanisms proposed include reduced risk factors, distal occlusion, smaller infarcts, and shorter time-to-treatment, but no direct data or analysis on the exponential nature of neuronal deterioration or on how rapid treatment modifies that trajectory.",
          "pmid": "33527883",
          "title": "Pre-stroke physical activity and admission stroke severity: A systematic review.",
          "analysis_method": "llm"
        },
        {
          "stance": "conflict",
          "confidence": "high",
          "reasoning": "The proposed mechanism asserts that rapid treatment is crucial because neuronal deterioration proceeds exponentially during ischemia, implying a strong, accelerating time\u2011dependence of benefit. The abstract explicitly reports that, in this dataset, there was no interaction between time to treatment and the effect of endovascular therapy (EVT) versus medical management within 24 hours, and concludes there is no interaction by time. Although benefit becomes statistically nonsignificant after ~13 hours in categorical analyses, the primary stated result is that EVT benefit does not significantly vary with onset\u2011to\u2011puncture time, which conflicts with a mechanism emphasizing strong, exponential time sensitivity of treatment effect.",
          "key_findings": "Post hoc analysis of a randomized trial of EVT vs medical management in large infarct core strokes (n=451) examined onset\u2011to\u2011expected arterial puncture time (OPT) as both categorical (<6, 6\u2013<12, 12\u201324 hours) and continuous. EVT showed higher rates of favorable 90\u2011day outcomes than medical management within OPT <6 hours (44.4% vs 29.9%, adjusted OR 2.78) and 6\u201312 hours (45.7% vs 29.6%, adjusted OR 2.39), but not clearly beyond 12 hours (51.6% vs 41.4%, adjusted OR 2.05, 95% CI 0.88\u20134.77). The benefit became statistically nonsignificant after 13 hours 22 minutes, yet the authors report no significant interaction between time and treatment effect (all p for interaction >0.10) and conclude that EVT is associated with improved outcomes within 24 hours with no interaction by time.",
          "pmid": "39652807",
          "title": "Association Between Time to Treatment and Outcomes of Endovascular Therapy vs Medical Management in Patients With Large Ischemic Stroke.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract shows that earlier thrombolytic treatment after acute myocardial infarction reduces in-hospital mortality, emphasizing that rapid treatment is beneficial. However, it does not discuss ischemia-related neuronal deterioration, exponential damage kinetics, or any statistical modeling of exponential deterioration. Thus it supports a general \u2018time is tissue\u2019 concept but does not address the specific proposed mechanism about exponential neuronal deterioration during ischemia.",
          "key_findings": "In a registry of 71,253 AMI patients treated with t-PA, in-hospital death rates increased progressively with increasing delays in t-PA administration, with the lowest mortality in those treated within 2 hours of symptom onset. No significant association was found between time to t-PA and recurrent AMI, myocardial ischemia, cardiogenic shock, major bleeding, or stroke, while sustained ventricular arrhythmias declined with longer time to treatment.",
          "pmid": "9708650",
          "title": "Impact of time to treatment with tissue plasminogen activator on morbidity and mortality following acute myocardial infarction (The second National Registry of Myocardial Infarction).",
          "analysis_method": "llm"
        },
        {
          "stance": "support",
          "confidence": "medium",
          "reasoning": "The proposed mechanism asserts that rapid treatment is crucial because neuronal deterioration during ischemia progresses in an accelerating (effectively exponential) fashion, so shorter onset-to-revascularization time should be strongly associated with better outcomes. The abstract reports that shorter onset-to-revascularization time independently predicts favorable clinical outcome in multivariable analysis of thrombectomy patients, which directly supports the importance of rapid treatment, though it does not explicitly characterize the deterioration as exponential.",
          "key_findings": "In multivariable analysis of Solitaire FR thrombectomy patients, a short onset-to-revascularization time was an independent predictor of favorable 90-day functional outcome (mRS \u22642), alongside higher baseline ASPECTS and SPAN-100 status. This indicates that faster reperfusion is associated with better outcomes, consistent with the mechanism that rapid treatment is crucial during ongoing ischemic neuronal injury.",
          "pmid": "24557701",
          "title": "Impact of age and baseline NIHSS scores on clinical outcomes in the mechanical thrombectomy using solitaire FR in acute ischemic stroke study.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates how time from symptom onset to balloon inflation modifies the comparative clinical outcomes of two anticoagulation strategies during primary PCI. It does not analyze or model the temporal dynamics of neuronal (or even myocardial) deterioration as an exponential process, nor does it present evidence that rapid treatment is crucial specifically because of an exponential pattern of neuronal injury. The focus is on treatment\u2013time interaction for drug efficacy and safety, not on the statistical/mechanistic form of tissue deterioration.",
          "key_findings": "In STEMI patients undergoing primary PCI, bivalirudin versus UFH plus GPI was associated with higher 30-day and three\u2011year MACE and stent thrombosis in those with symptom\u2011to\u2011balloon time \u22643 hours, with no significant differences when symptom\u2011to\u2011balloon time was >3 hours. Bivalirudin was an independent predictor of MACE at 30 days and three years only in the short symptom\u2011to\u2011balloon group.",
          "pmid": "27753600",
          "title": "Impact of time to treatment on the effects of bivalirudin vs. glycoprotein IIb/IIIa inhibitors and heparin in patients undergoing primary percutaneous coronary intervention: insights from the HORIZONS-AMI trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "medium",
          "reasoning": "The abstract shows that shorter time to reperfusion in myocardial infarction is associated with smaller infarct size and lower 1-year mortality, which is broadly consistent with the idea that rapid treatment matters. However, the proposed mechanism is specifically about an exponential time course of neuronal deterioration during ischemia. This study examines myocardial tissue, not neurons, and does not characterize the time\u2013damage relationship as exponential or provide statistical modeling of such a curve. Therefore it does not directly support or refute the specific statistical/neural mechanism.",
          "key_findings": "In STEMI patients reperfused within 5 hours, a delay \u22653 hours vs <3 hours was associated with larger infarct size on MRI and higher 1-year mortality (9.2% vs 4.0%), while reperfusion success metrics (TIMI 3 flow, myocardial blush 2/3) did not differ by delay.",
          "pmid": "25060015",
          "title": "Impact of delay to reperfusion on reperfusion success, infarct size, and clinical outcomes in patients with ST-segment elevation myocardial infarction: the INFUSE-AMI Trial (INFUSE-Anterior Myocardial Infarction).",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "medium",
          "reasoning": "The abstract shows that earlier (\u226472 h) stroke rehabilitation leads to better functional outcomes than starting between 72 h and 7 days, which supports the clinical importance of rapid treatment. However, it does not address or quantify an exponential time\u2013outcome or neuronal deterioration curve during ischemia, nor does it distinguish neuronal ischemic processes from the effects of rehabilitation timing. Thus it does not directly test or validate the proposed exponential statistical mechanism.",
          "key_findings": "In a randomized trial of acute ischemic stroke patients, ultraearly rehabilitation (within 72 hours of onset) produced significantly better NIHSS, Barthel Index, and Fugl-Meyer Assessment scores at 1 and 3 months compared with early rehabilitation initiated between 72 hours and 7 days, even after adjustment for multiple confounders (P < 0.001).",
          "pmid": "34493977",
          "title": "Effects of Different Intervention Time Points of Early Rehabilitation on Patients with Acute Ischemic Stroke: A Single-Center, Randomized Control Study.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract examines gender differences in short-term outcomes and bleeding risk in STEMI patients receiving ticagrelor, with some mention of prehospital delays, but it does not analyze outcomes as a function of treatment timing or model any exponential pattern of neuronal (or even myocardial) deterioration. It provides no direct evidence about the proposed statistical mechanism that rapid treatment is crucial due to exponential neuronal deterioration during ischemia.",
          "key_findings": "Women with STEMI were older, had higher TIMI risk scores, longer prehospital delays, and better initial TIMI flow; female gender was an independent predictor of higher short-term all-cause mortality despite adjustment; women had higher crude rates of major bleeding, though female sex was not an independent bleeding predictor after multivariable adjustment; no interaction was found between gender and the efficacy or safety of prehospital vs in-hospital ticagrelor administration.",
          "pmid": "28939567",
          "title": "Association between gender and short-term outcome in patients with ST elevation myocardial infraction participating in the international, prospective, randomised Administration of Ticagrelor in the catheterisation Laboratory or in the Ambulance for New ST elevation myocardial Infarction to open the Coronary artery (ATLANTIC) trial: a prespecified analysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract examines whether dual antiplatelet therapy (clopidogrel plus aspirin) initiated within 12 hours improves outcomes versus aspirin alone in minor stroke/TIA, but it does not analyze how risk changes as a function of time-from-onset nor does it address an exponential pattern of neuronal deterioration. The mention of treatment within 12 hours is a trial inclusion/randomization window, not evidence about the statistical shape (e.g., exponential) of neuronal injury over time, so it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "Among patients randomized within 12 hours of minor stroke/TIA, dual antiplatelet therapy reduced 90-day recurrent ischemic stroke compared with aspirin alone (6.57% vs 8.91%) without increasing hemorrhagic events; multivariable Cox modeling indicated randomization within 12 hours was an independent predictor of ischemic stroke events, but the abstract does not characterize the time course or exponential nature of neuronal deterioration during ischemia.",
          "pmid": "27001965",
          "title": "Treatment Effect of Clopidogrel Plus Aspirin Within 12\u00a0Hours of Acute Minor Stroke or Transient Ischemic Attack.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses that earlier treatment (early vs late Gp IIb-IIIa inhibitor administration) affects preprocedural flow and some clinical outcomes in STEMI, but it does not characterize or analyze neuronal deterioration, exponential damage dynamics, or ischemic injury mechanisms at the neuronal level. The proposed mechanism is about the statistical/exponential nature of neuronal deterioration during ischemia and the crucial importance of rapid treatment in that specific context, which is not addressed here.",
          "key_findings": "Early administration of Gp IIb-IIIa inhibitors in primary angioplasty for STEMI increased preprocedural TIMI 3 flow and ST-segment resolution, with non-significant mortality benefit overall but improved survival for early abciximab versus late. Time-to-treatment is mentioned as a determinant of mortality in primary angioplasty, but without mechanistic or quantitative treatment of exponential neuronal deterioration.",
          "pmid": "18474534",
          "title": "Early glycoprotein IIb-IIIa inhibitors in primary angioplasty (EGYPT) cooperation: an individual patient data meta-analysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates magnesium treatment effects in lacunar stroke and examines whether benefits are explained by baseline factors including time to treatment, but it does not analyze neuronal deterioration over time, exponential damage dynamics, or show outcome differences as a function of treatment delay. It explicitly notes that the positive effect in LACS cannot be ascribed to time to treatment, but this pertains to effect modification by delay, not to evidence about an exponential deterioration process.",
          "key_findings": "In the IMAGES trial LACS subgroup, intravenous magnesium showed beneficial effects on Barthel Index <95, modified Rankin Scale >1, and global outcome. The magnesium\u2013LACS interaction remained significant after adjusting for multiple baseline variables, and the authors state that the positive treatment effect cannot be attributed to severity, time to treatment, blood pressure, or other baseline factors. No analysis of exponential neuronal deterioration or specific time-dependent outcome gradients is presented.",
          "pmid": "17347471",
          "title": "Magnesium for treatment of acute lacunar stroke syndromes: further analysis of the IMAGES trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "medium",
          "reasoning": "The abstract shows that longer ischemia and door-to-balloon times are associated with worse myocardial and microvascular perfusion, supporting the importance of rapid treatment. However, it does not address or model the *exponential* nature of deterioration; it only demonstrates that greater delays worsen outcomes, without specifying the functional (e.g., exponential) time\u2013damage relationship.",
          "key_findings": "In 2,056 STEMI patients, longer symptom onset-to-balloon time and door-to-balloon time were independent predictors of absent microvascular perfusion (MBG 0/1) and absent ST-segment resolution (STR <30%). Treatment delays were associated with greater microcirculatory injury and higher 3-year mortality. The analysis did not characterize the time\u2013damage relationship as exponential or otherwise describe its statistical form.",
          "pmid": "26738667",
          "title": "Effect of Ischemia Duration and Door-to-Balloon Time on Myocardial Perfusion in ST-Segment Elevation Myocardial Infarction: An Analysis From HORIZONS-AMI Trial (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction).",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract shows that shorter symptom-to-balloon time improves coronary flow, left ventricular function, and 3\u2011year survival after myocardial infarction, supporting the general importance of rapid reperfusion. However, the proposed mechanism is specifically about an exponential time-course of neuronal deterioration during ischemia, which involves neural tissue and a particular statistical/kinetic form (exponential decline). This study focuses on cardiac tissue, not neurons, and does not analyze or model deterioration or benefit as an exponential function of time, so it neither confirms nor refutes the specific proposed mechanism.",
          "key_findings": "In STEMI patients treated with primary PCI, symptom-to-balloon time \u22655 h was associated with significantly higher 3\u2011year mortality (adjusted HR 2.44, 95% CI 1.31\u20134.54) compared with <5 h; longer delays were associated with worse left ventricular ejection fraction (\u226440% more frequent with longer delays; p=0.036) and lower rates of TIMI 3 flow (p=0.002). These findings show that earlier treatment improves cardiac outcomes but do not address neuronal ischemia or an exponential deterioration model.",
          "pmid": "20494656",
          "title": "Time to treatment and three-year mortality after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction-a DANish Trial in Acute Myocardial Infarction-2 (DANAMI-2) substudy.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "medium",
          "reasoning": "The abstract shows that longer time to treatment is associated with higher mortality in certain higher-risk myocardial infarction patients, implying that treatment delay worsens outcome. However, it does not address the proposed statistical/mechanistic claim that neuronal deterioration during ischemia follows an exponential time course, nor does it discuss neuronal tissue or ischemic stroke. The result is about cardiac outcomes and time-to-reperfusion, not about the exponential nature of neuronal deterioration, so it cannot be taken as direct support or conflict for that specific mechanism.",
          "key_findings": "In 1,336 acute myocardial infarction patients undergoing primary PTCA, unadjusted 6\u2011month mortality in the higher-risk group rose from 4.8% to 12.9% with longer time to reperfusion (up to 6 hours), while mortality in the low-risk group remained constant. Time to reperfusion was associated with mortality in univariate analysis (OR 1.35, 95% CI 1.06\u20131.73, p = 0.017) but was not an independent predictor in multivariate analysis.",
          "pmid": "12031722",
          "title": "Relation of time to treatment and mortality in patients with acute myocardial infarction undergoing primary coronary angioplasty.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract examines late potentials and infarct-related artery patency after different reperfusion strategies (systemic thrombolysis vs primary PTCA) and their association with LPs. It does not analyze or model time-dependent, exponential neuronal deterioration during ischemia, nor does it address the urgency of treatment in terms of a statistical or exponential decay process. The study focuses on cardiac electrophysiologic outcomes and coronary patency, not neuronal injury kinetics or the exponential nature of ischemic damage.",
          "key_findings": "Primary PTCA led to higher patency rates and less severe residual stenosis compared with systemic thrombolysis, but the prevalence of late potentials was similar between groups. Occluded infarct-related artery was the only independent predictor of late potentials. No data or analysis pertains to exponential neuronal deterioration or time-critical, exponential treatment effects.",
          "pmid": "9493040",
          "title": "Prevalence of late potentials after myocardial infarction treated with systemic thrombolysis or primary percutaneous transluminal coronary angioplasty.",
          "analysis_method": "llm"
        }
      ]
    },
    {
      "feature_name": "Diabetes mellitus",
      "mechanism": {
        "mechanism_type": "biological",
        "description": "Chronic hyperglycemia and resulting endothelial dysfunction affect alteplase potency against complicated atherosclerotic plaques.",
        "evidence_level": "moderate"
      },
      "query": "(stroke OR alteplase OR thrombolysis OR \"ischemic stroke\") AND \"Diabetes mellitus\" AND (\"pathophysiology\" OR \"mechanism\" OR \"causal\" OR \"etiology\" OR \"interaction\") AND (\"atherosclerotic\" OR \"hyperglycemia\" OR \"endothelial\") AND (Clinical Trial[PT] OR Review[PT] OR Meta-Analysis[PT])",
      "total_abstracts": 20,
      "support_count": 0,
      "conflict_count": 0,
      "neutral_count": 20,
      "support_percentage": 0.0,
      "conflict_percentage": 0.0,
      "support_ratio": 0.0,
      "abstracts_analyzed": [
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates cardiovascular outcomes of oral semaglutide in high\u2011risk type 2 diabetes but does not discuss alteplase, thrombolysis, plaque lysis, or how chronic hyperglycemia\u2013induced endothelial dysfunction might alter alteplase potency against complicated atherosclerotic plaques. It focuses on event reduction with a GLP\u20111 agonist, not on thrombolytic response or mechanistic interactions between glycemic status, endothelium, and alteplase.",
          "key_findings": "Oral semaglutide reduced major adverse cardiovascular events (HR 0.86) versus placebo in patients with type 2 diabetes and ASCVD and/or CKD, with similar serious adverse event rates; no data are presented on alteplase use, responses to thrombolytic therapy, or direct measures of endothelial dysfunction relevant to alteplase potency.",
          "pmid": "40162642",
          "title": "Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates cardiovascular and renal outcomes of dapagliflozin in type 2 diabetes but does not mention alteplase, thrombolysis, plaque lysis, or how chronic hyperglycemia or endothelial dysfunction might alter alteplase potency against complicated atherosclerotic plaques. It focuses on clinical event rates (MACE, heart failure, renal composite) and safety, not on thrombolytic response or plaque-level mechanisms.",
          "key_findings": "Dapagliflozin was noninferior to placebo for MACE, reduced cardiovascular death or hospitalization for heart failure primarily via reduced heart failure hospitalizations, and lowered renal events, with some increased risk of diabetic ketoacidosis and serious genital infections. No data are presented on alteplase use, response to thrombolysis, plaque characteristics, or endothelial modulation of thrombolytic efficacy.",
          "pmid": "30415602",
          "title": "Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses stroke prevention strategies and risk factor management, including diabetes and insulin resistance, but does not address alteplase, thrombolytic efficacy, endothelial dysfunction, or how chronic hyperglycemia might alter alteplase potency against atherosclerotic plaques.",
          "key_findings": "Primary and secondary prevention of ischemic stroke involve managing hypertension, diabetes, lipid disorders, insulin resistance, and using antiplatelets, anticoagulation, carotid interventions, and patent foramen ovale closure; cerebral hemorrhage prevention focuses on blood pressure control, reduced alcohol intake, and left atrial appendage occlusion.",
          "pmid": "32299593",
          "title": "Primary and Secondary Prevention of\u00a0Ischemic Stroke and Cerebral\u00a0Hemorrhage: JACC Focus Seminar.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates cardiovascular outcomes of oral semaglutide with or without SGLT2 inhibitor use in people with type 2 diabetes. It does not mention alteplase, acute thrombolysis, endothelial dysfunction as a modifier of alteplase potency, or detailed plaque-level thrombolytic responses. While it concerns diabetes, atherosclerotic disease, and cardiovascular outcomes, it provides no mechanistic data about how chronic hyperglycemia or endothelial dysfunction alter alteplase efficacy against complicated atherosclerotic plaques.",
          "key_findings": "Oral semaglutide reduced major adverse cardiovascular events by 14% versus placebo in patients with type 2 diabetes and ASCVD and/or CKD. The treatment effect was similar regardless of baseline or in-trial SGLT2 inhibitor use (no significant interaction). Safety profiles were similar with or without concomitant SGLT2i. No information was provided on alteplase, thrombolysis, or mechanistic effects of hyperglycemia/endothelial dysfunction on alteplase potency.",
          "pmid": "40156843",
          "title": "Oral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses diabetes epidemiology, diagnosis, classification, complications, and lifestyle interventions, but does not mention alteplase, thrombolysis, plaque-specific treatment response, or how chronic hyperglycemia/endothelial dysfunction modulate alteplase potency. Therefore it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "Diabetes and pre-diabetes prevalence and diagnosis are described, including microvascular and macrovascular complications such as stroke and cardiovascular disease. However, no mechanistic data or therapeutic response information involving alteplase or its interaction with atherosclerotic plaques in the context of hyperglycemia/endothelial dysfunction is provided.",
          "pmid": "31470636",
          "title": "From Pre-Diabetes to Diabetes: Diagnosis, Treatments and Translational Research.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates cardiovascular and renal outcome effects of SGLT2 inhibitors in type 2 diabetes but does not address alteplase, thrombolysis, plaque-level responses, or how chronic hyperglycemia\u2013induced endothelial dysfunction might modulate alteplase potency against complicated atherosclerotic plaques.",
          "key_findings": "SGLT2 inhibitors reduced major adverse cardiovascular events (11% reduction overall, benefit limited to those with established ASCVD), reduced cardiovascular death or heart failure hospitalization (23% reduction) regardless of ASCVD or HF history, and reduced progression of renal disease (45% reduction) with effect sizes varying by baseline renal function. No data are presented on alteplase use, thrombolytic efficacy, or mechanistic interactions between hyperglycemia, endothelial dysfunction, and plaque-level thrombolysis.",
          "pmid": "30424892",
          "title": "SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract links diabetes, hyperglycemia, endothelial dysfunction (via reduced nitric oxide and increased reactive oxygen species), inflammation, and atherothrombotic progression, but it does not mention alteplase, thrombolytic therapy, or any change in alteplase potency or efficacy against atherosclerotic plaques. Thus it is mechanistically related upstream (hyperglycemia/endothelial dysfunction/atherothrombosis) but does not provide direct evidence for or against the proposed effect on alteplase potency.",
          "key_findings": "Hyperglycemia, hyperinsulinemia, and insulin resistance alter vascular homeostasis; reduced nitric oxide and increased reactive oxygen species promote inflammation, leading to atherothrombotic progression and myocardial dysfunction in diabetes. No data are presented on thrombolytic agents, including alteplase, or their interaction with diabetic vasculopathy or plaque complexity.",
          "pmid": "33813813",
          "title": "Epidemiology, Pathophysiology, Diagnosis and Treatment of Heart Failure in Diabetes.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates clinical cardiovascular and kidney outcomes of SGLT2 inhibitors in type 2 diabetes but does not mention alteplase, thrombolysis, endothelial dysfunction, or how chronic hyperglycemia might alter alteplase potency against atherosclerotic plaques. It focuses on event rates (MACE, HF hospitalization, kidney outcomes) rather than mechanistic interactions between glycemic state, endothelium, and thrombolytic efficacy.",
          "key_findings": "SGLT2 inhibitors reduced risk of major adverse cardiovascular events (HR 0.90), hospitalization for heart failure/CV death (HR 0.78), and kidney composite outcomes (HR 0.62) in patients with type 2 diabetes, with similar benefits irrespective of baseline atherosclerotic cardiovascular disease status. No data are provided on alteplase response, plaque-specific thrombolysis, or endothelial dysfunction mechanisms.",
          "pmid": "33031522",
          "title": "Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses chronic inflammation, insulin resistance, advanced glycation end-products (AGEs), RAGE expression, and endothelial dysfunction in PCOS, as well as cardiovascular risk markers related to thrombosis and endothelial damage. However, it does not mention hyperglycemia per se, alteplase (tPA), thrombolytic therapy, or the drug\u2019s potency/effectiveness against complicated atherosclerotic plaques. Thus it neither supports nor contradicts the specific mechanism about chronic hyperglycemia altering alteplase potency on atherosclerotic plaques.",
          "key_findings": "PCOS is associated with low-grade chronic inflammation, insulin resistance, elevated AGEs and RAGE expression, and markers of endothelial dysfunction and thrombosis (e.g., CRP, ADMA, homocysteine, PAI-1, VEGF). PCOS patients have increased cardiovascular and atherosclerosis risk, but no data are presented regarding alteplase activity or drug response in this context.",
          "pmid": "33917519",
          "title": "Chronic Low Grade Inflammation in Pathogenesis of PCOS.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates cardiovascular outcomes and glycaemic effects of evolocumab in patients with and without diabetes, but does not involve alteplase, thrombolysis, or direct measures of plaque response to thrombolytic therapy. It does not address how chronic hyperglycaemia or endothelial dysfunction might alter alteplase potency against complicated atherosclerotic plaques, so it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "Evolocumab reduced cardiovascular events similarly in patients with and without diabetes; it did not increase new-onset diabetes or worsen HbA1c or fasting plasma glucose. No data are presented on alteplase, thrombolytic response, or mechanism-specific interactions between hyperglycaemia, endothelial dysfunction, and alteplase efficacy on atherosclerotic plaques.",
          "pmid": "28927706",
          "title": "Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract links diabetes, hyperglycemia, and worse stroke outcomes in general, but it does not mention alteplase, thrombolysis, endothelial dysfunction in relation to treatment response, or atherosclerotic plaque-specific effects. Therefore it neither supports nor contradicts the specific mechanism about hyperglycemia/endothelial dysfunction altering alteplase potency against complicated plaques.",
          "key_findings": "Diabetes and hyperglycemia increase stroke risk and are associated with poorer clinical outcomes and higher mortality after ischemic stroke, but no data are presented on alteplase effectiveness, plaque biology, or endothelial dysfunction in the context of thrombolytic therapy.",
          "pmid": "27079344",
          "title": "Diabetes and Stroke: Epidemiology, Pathophysiology, Pharmaceuticals and Outcomes.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses that diabetes and hyperglycemia aggravate atherosclerosis and mentions the need for mechanism-based therapies, but it does not address endothelial dysfunction in the context of alteplase potency, thrombolysis, or treatment response to atherosclerotic plaque\u2013related events. No data or claims are made about how chronic hyperglycemia or endothelial dysfunction modify alteplase effectiveness.",
          "key_findings": "The review notes that: (1) atherosclerosis is a major cause of cardiovascular mortality in diabetes; (2) diabetes aggravates pathobiological mechanisms underlying atherosclerosis; and (3) current therapies focus on systemic risk factors like hyperglycemia and dyslipidemia and do not adequately target diabetes-exacerbated mechanisms. Alteplase, thrombolysis, or drug potency against complicated plaques are not mentioned.",
          "pmid": "39805949",
          "title": "Atherosclerosis in diabetes mellitus: novel mechanisms and mechanism-based therapeutic approaches.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract links diabetes and hyperglycemia to increased stroke risk and worse stroke outcomes, but it does not mention alteplase, thrombolysis, endothelial dysfunction in the context of alteplase response, or effects on atherosclerotic plaque lysis. Thus it does not directly address how chronic hyperglycemia or endothelial dysfunction might alter alteplase potency against complicated atherosclerotic plaques.",
          "key_findings": "Diabetes increases stroke risk (1.5\u20132\u00d7), with higher risk with longer diabetes duration and possibly greater risk in women. Mechanisms include large artery atherosclerosis, small vessel disease, and cardiac embolism. Hyperglycemia is associated with worse outcomes in acute ischemic stroke and poorer post-stroke outcomes and higher recurrence risk in people with diabetes. Certain diabetes drugs (pioglitazone, GLP-1 receptor agonists) protect against stroke independently of glycemic control. No discussion of thrombolytic therapy or alteplase efficacy is provided.",
          "pmid": "36592968",
          "title": "Diabetes and Stroke: What Are the Connections?",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract focuses on statin safety, adverse events, and vascular outcomes but does not address alteplase, thrombolysis, endothelial dysfunction from chronic hyperglycemia, or how these factors interact with atherosclerotic plaque response to alteplase.",
          "key_findings": "Describes statin effects on LDL reduction, risks of muscle injury, hepatotoxicity, incident diabetes, and stroke subtypes; notes possible increase in hemorrhagic stroke but net reduction in atherothrombotic and total stroke. No mention of alteplase, hyperglycemia-related endothelial dysfunction, or thrombolytic potency against complicated plaques.",
          "pmid": "30580575",
          "title": "Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates the effects of SGLT2 inhibitors on major adverse cardiovascular events and mortality across several patient populations. It does not discuss alteplase, thrombolysis, acute ischemic stroke treatment, or mechanistic links between chronic hyperglycemia\u2013induced endothelial dysfunction and alteplase potency against complicated atherosclerotic plaques. Therefore, it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "SGLT2 inhibitors reduced overall MACE by 9%, mainly via reduced cardiovascular death (especially heart failure death and sudden cardiac death), with no significant effect on myocardial infarction or stroke; these effects were consistent across subgroups defined by atherosclerotic cardiovascular disease, diabetes, kidney function, and other characteristics.",
          "pmid": "38583093",
          "title": "Sodium-Glucose Cotransporter-2 Inhibitors and Major Adverse Cardiovascular Outcomes: A SMART-C Collaborative Meta-Analysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses oxidized LDL-induced atherogenesis, risk factors including diabetes mellitus, and general therapeutic approaches targeting lipids. It does not mention chronic hyperglycemia, endothelial dysfunction, alteplase, thrombolysis, or how glycemic status affects alteplase potency against complicated atherosclerotic plaques. Therefore it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "Oxidized LDL accumulation in the arterial intima initiates atherosclerosis; plaques can rupture leading to thrombosis and major cardiovascular events; risk factors include obesity and diabetes mellitus; lipid-lowering strategies such as statins and management of LDL/HDL are emphasized as therapeutic approaches.",
          "pmid": "33014272",
          "title": "Mechanistic Insights into the Oxidized Low-Density Lipoprotein-Induced Atherosclerosis.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract links diabetes, hyperglycemia, and vascular dysfunction to atherosclerosis and worse cardiovascular outcomes, but it does not mention alteplase, thrombolytic potency, or treatment effects on complicated plaques specifically. Therefore, it neither supports nor conflicts with the proposed mechanism about hyperglycemia-induced endothelial dysfunction altering alteplase potency.",
          "key_findings": "Diabetes causes metabolic abnormalities that induce vascular dysfunction and predispose to atherosclerosis; diabetic patients have higher risks of myocardial infarction, stroke, amputation, and death, and worse outcomes after revascularization. The abstract does not address alteplase or any thrombolytic drug effects.",
          "pmid": "12020339",
          "title": "Diabetes and atherosclerosis: epidemiology, pathophysiology, and management.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract shows that diabetes and acute hyperglycemia are associated with poorer overall stroke outcomes, but it does not examine alteplase use, thrombolysis response, endothelial dysfunction, or effects on complicated atherosclerotic plaques. Therefore it does not directly address the proposed mechanism about hyperglycemia altering alteplase potency.",
          "key_findings": "Meta-analysis of 39 studies (n=359,783) found diabetes prevalence of ~28% in acute stroke patients (33% in ischemic, 26% in hemorrhagic). Most included studies reported that diabetes and acute hyperglycemia were associated with poorer outcomes after stroke (higher mortality, worse neurological/functional outcomes, longer stay, higher readmission, and recurrence). No data on alteplase efficacy, plaque biology, or endothelial function are presented.",
          "pmid": "30220102",
          "title": "Prevalence of diabetes and its effects on stroke\u00a0outcomes: A meta-analysis and literature review.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses stress-induced hyperglycemia, its mechanisms (insulin resistance, decreased insulin secretion), its association with worse outcomes including myocardial infarction and ischemic stroke, and its management. It does not mention alteplase, thrombolysis, endothelial dysfunction as a mediator of alteplase potency, or effects on complicated atherosclerotic plaques. Therefore, it neither supports nor contradicts the specific proposed mechanism.",
          "key_findings": "Stress-induced hyperglycemia (>180 mg/dL) in non-diabetic hospitalized patients is common, driven by illness-related insulin resistance and reduced insulin secretion; it is associated with increased mortality and worse outcomes in conditions such as myocardial infarction and ischemic stroke, and requires careful in-hospital management and discharge planning due to future diabetes risk.",
          "pmid": "35959169",
          "title": "Stress-Induced Hyperglycemia: Consequences and Management.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "medium",
          "reasoning": "The abstract links chronic hyperglycemia to endothelial damage, accelerated atherosclerosis, and worse outcomes/less benefit from IV tissue plasminogen activator in acute ischemic stroke, but it does not specifically examine alteplase potency against complicated atherosclerotic plaques or provide mechanistic data on how endothelial dysfunction alters alteplase\u2019s thrombolytic effectiveness at plaque sites.",
          "key_findings": "1) Chronic hyperglycemia and advanced glycation end-products promote accelerated atherosclerosis via endothelial damage and cellular dysfunction. 2) Diabetic patients with hyperglycemia who experience acute ischemic stroke are more likely to die or be severely disabled and are less likely to benefit from IV tissue plasminogen activator. 3) Experimental stroke models show that chronic hyperglycemia leads to deficits in cerebrovascular structure and function (increased edema, neovascularization, protease expression, altered vascular reactivity and tone). The abstract, however, does not directly address alteplase potency against complicated atherosclerotic plaques.",
          "pmid": "35216512",
          "title": "Diabetes and Ischemic Stroke: An Old and New Relationship an Overview of the Close Interaction between These Diseases.",
          "analysis_method": "llm"
        }
      ]
    },
    {
      "feature_name": "Diabetes mellitus",
      "mechanism": {
        "mechanism_type": "pharmacological",
        "description": "Acute glycemic levels at stroke onset may alter alteplase effectiveness, necessitating control at these pivotal times.",
        "evidence_level": "speculative"
      },
      "query": "(stroke OR alteplase OR thrombolysis OR \"ischemic stroke\") AND \"Diabetes mellitus\" AND (\"pharmacokinetics\" OR \"pharmacodynamics\" OR \"dose-response\" OR \"clearance\") AND (\"effectiveness\" OR \"necessitating\" OR \"alteplase\") AND (Clinical Trial[PT] OR Review[PT] OR Meta-Analysis[PT])",
      "total_abstracts": 10,
      "support_count": 0,
      "conflict_count": 0,
      "neutral_count": 10,
      "support_percentage": 0.0,
      "conflict_percentage": 0.0,
      "support_ratio": 0.0,
      "abstracts_analyzed": [
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract examines associations between short sleep duration and long-term risks of mortality and various cardiometabolic diseases, including stroke and diabetes, in prospective cohorts. It does not assess acute glycemic levels at stroke onset, alteplase effectiveness, or how glycemic control at the time of stroke affects thrombolytic response. Therefore, it neither supports nor contradicts the proposed pharmacological mechanism.",
          "key_findings": "Short sleep duration (<6 hours) is associated with increased risks of mortality (RR 1.12) and several chronic conditions such as diabetes mellitus (RR 1.37), hypertension (RR 1.17), cardiovascular disease (RR 1.16), coronary heart disease (RR 1.26), and obesity (RR 1.38). Associations with stroke are mentioned as an outcome of interest but not specifically quantified here, and no data relate to acute stroke treatment or alteplase response.",
          "pmid": "27743803",
          "title": "Short sleep duration and health outcomes: a systematic review, meta-analysis, and meta-regression.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates how prior stroke and/or diabetes history modify the comparative effects of low- vs standard-dose alteplase, but it does not measure or analyze acute glycemic levels at stroke onset, nor whether glycemic control at that time alters alteplase effectiveness. Thus it neither supports nor contradicts the proposed mechanism about acute glycemia affecting alteplase efficacy.",
          "key_findings": "In the ENCHANTED trial alteplase-dose arm (n=3288), a history of prior stroke and/or diabetes mellitus was not associated with poorer 90-day outcomes after thrombolysis and did not modify the relative effects of low-dose (0.6 mg/kg) versus standard-dose (0.9 mg/kg) alteplase on functional outcome, mortality, or symptomatic intracerebral hemorrhage. The study did not report on acute blood glucose levels or their management at stroke onset.",
          "pmid": "29571842",
          "title": "Comparative effects of low-dose versus standard-dose alteplase in ischemic patients with prior stroke and/or diabetes mellitus: The ENCHANTED trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses long-term antithrombotic therapy for atrial fibrillation, stroke risk stratification (CHADS2), and choice of oral anticoagulants versus antiplatelets. It does not address acute glycemic levels at stroke onset, alteplase (tPA) use, or how glycemia might alter alteplase effectiveness. Therefore, it neither supports nor conflicts with the proposed mechanism.",
          "key_findings": "Guideline-based recommendations for antithrombotic therapy in atrial fibrillation: no therapy or aspirin for low CHADS2, oral anticoagulation (preferably dabigatran 150 mg bid) for intermediate and high CHADS2 scores, with emphasis on net clinical benefit between stroke prevention and bleeding risk. No mention of acute stroke treatment, alteplase, or glycemic control.",
          "pmid": "22315271",
          "title": "Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract examines diabetes status and outcomes with different anticoagulant regimens (bivalirudin vs heparin plus GPI) in STEMI patients undergoing PCI. It does not assess acute glycemic levels, glucose control at the time of an acute cerebrovascular event, or alteplase effectiveness in stroke. Therefore, it neither supports nor contradicts the proposed mechanism about acute glycemia modifying alteplase efficacy in stroke.",
          "key_findings": "In STEMI patients with diabetes undergoing primary PCI, bivalirudin compared with heparin plus GPI was associated with lower cardiac death at 30 days and 1 year and lower 30-day stroke rates, with similar rates of major adverse cardiac events, bleeding, and stent thrombosis. The effects did not differ significantly between patients with and without diabetes. No data on acute glycemic levels or alteplase in stroke are provided.",
          "pmid": "21777884",
          "title": "Impact of diabetes mellitus on the safety and effectiveness of bivalirudin in patients with acute myocardial infarction undergoing primary angioplasty: analysis from the HORIZONS-AMI (Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction) trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates outcomes of mineralocorticoid receptor antagonist use in heart failure patients with and without diabetes. It does not involve stroke, alteplase, acute glycemic levels at stroke onset, or any assessment of how glucose control might alter thrombolytic effectiveness.",
          "key_findings": "In the EVEREST trial placebo arm, discharge use of mineralocorticoid receptor antagonists in heart failure patients with reduced ejection fraction was around 60% irrespective of diabetes status, and after adjustment, MRA use was not associated with differences in mortality or composite cardiovascular death/heart failure hospitalization; diabetes did not modify MRA therapy effectiveness.",
          "pmid": "25060414",
          "title": "Mineralocorticoid receptor antagonist use in hospitalized patients with heart failure, reduced ejection fraction, and diabetes mellitus (from the EVEREST Trial).",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract examines effects of oral contraceptives on insulin resistance, glucose tolerance, lipids, and haemostatic markers in non-diabetic and insulin-dependent diabetic women. It does not involve stroke patients, alteplase treatment, or the impact of acute glycemic levels at stroke onset on thrombolytic effectiveness. Any discussion of glycemic control or thrombosis risk is chronic and prophylactic, not acute or treatment-related, so it neither supports nor contradicts the proposed alteplase-related mechanism.",
          "key_findings": "Low-dose oral contraceptives containing newer gonane progestogens can induce insulin resistance and impair glucose tolerance in some non-diabetic women; in women with well-regulated IDDM, glycemic control was unchanged over one year of OC use. Lipoprotein profiles tended to show increased HDL and decreased LDL, and haemostatic changes suggested maintained balance between coagulation and fibrinolysis, with possibly increased fibrin formation in IDDM. No data involve acute stroke, alteplase therapy, or how acute blood glucose at stroke onset affects thrombolytic efficacy.",
          "pmid": "11894723",
          "title": "Pharmacodynamic effects of oral contraceptive steroids on biochemical markers for arterial thrombosis. Studies in non-diabetic women and in women with insulin-dependent diabetes mellitus.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates long-term management of newly diagnosed type 2 diabetes with gliclazide in a primary care setting and reports changes in chronic glycemic measures (FBG, PPBG, HbA1c) and complications. It does not involve acute stroke, alteplase use, or how acute glycemic levels at stroke onset influence thrombolytic effectiveness, nor does it address glycemic control at the time of stroke or reperfusion therapy.",
          "key_findings": "Two years of gliclazide therapy in newly diagnosed NIDDM patients led to significant improvements in fasting and postprandial blood glucose and HbA1c, modest improvements in lipids, BMI, blood pressure, and stable microalbuminuria with a slight increase in retinopathy. No data are presented on acute stroke events, alteplase administration, or how acute glycemia at stroke onset modifies alteplase effectiveness.",
          "pmid": "9439556",
          "title": "Management of newly diagnosed non-insulin-dependent diabetes mellitus in the primary care setting: effects of 2 years of gliclazide treatment--the Diadem Study.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses abciximab and its use with fibrinolytics including alteplase in ischaemic heart disease and myocardial infarction, but it does not mention acute glycemic levels, blood glucose control, or any effect of glycemia on alteplase effectiveness. Therefore it neither supports nor contradicts the proposed mechanism about glycemic modulation of alteplase response at stroke onset.",
          "key_findings": "Abciximab improves ischaemic outcomes in percutaneous coronary intervention and in combination with fibrinolytic agents such as tenecteplase, reteplase, and alteplase; TIMI-3 flow rates are higher with combination therapy versus abciximab alone and similar to full-dose fibrinolytic alone. High-risk patients including those with diabetes benefit more from abciximab, but there is no analysis of acute glycemic levels or their impact on alteplase efficacy, and the setting is coronary, not cerebral, ischaemia.",
          "pmid": "12749745",
          "title": "Abciximab: an updated review of its therapeutic use in patients with ischaemic heart disease undergoing percutaneous coronary revascularisation.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates acetylcysteine for prevention of contrast-induced nephropathy in patients undergoing coronary procedures. It does not address acute glycemic levels, stroke, alteplase, or thrombolytic effectiveness, so it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "Oral acetylcysteine did not significantly reduce the incidence of contrast nephropathy compared with placebo in at-risk patients undergoing coronary angiographic procedures; contrast volume, reduced ejection fraction, and creatinine clearance were associated with nephropathy risk. No data are presented on glucose levels, stroke, or alteplase response.",
          "pmid": "15687530",
          "title": "Effectiveness of acetylcysteine in prevention of contrast nephropathy.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract evaluates anticoagulant and stent strategies in STEMI and reports mortality, reinfarction, bleeding, and revascularization outcomes over 3 years. It does not examine acute glycemic levels, thrombolytic (alteplase) therapy, or any interaction between glycemia at stroke onset and alteplase effectiveness, so it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "Bivalirudin monotherapy vs heparin plus GPI showed lower all-cause and cardiac mortality, reinfarction, and major bleeding at 3 years; paclitaxel-eluting stents vs bare-metal stents reduced ischaemia-driven target lesion revascularization without affecting death, reinfarction, stroke, or stent thrombosis. No data on glycemic control or alteplase effectiveness are reported.",
          "pmid": "21665265",
          "title": "Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial.",
          "analysis_method": "llm"
        }
      ]
    },
    {
      "feature_name": "Diabetes mellitus",
      "mechanism": {
        "mechanism_type": "statistical",
        "description": "Poor pre-existing vascular health in diabetics correlates with worse post-thrombolysis outcomes.",
        "evidence_level": "strong"
      },
      "query": "(stroke OR alteplase OR thrombolysis OR \"ischemic stroke\") AND \"Diabetes mellitus\" AND (\"independent predictor\" OR \"confounding\" OR \"interaction effect\") AND (\"thrombolysis\" OR \"correlates\" OR \"diabetics\") AND (Clinical Trial[PT] OR Review[PT] OR Meta-Analysis[PT])",
      "total_abstracts": 13,
      "support_count": 0,
      "conflict_count": 1,
      "neutral_count": 12,
      "support_percentage": 0.0,
      "conflict_percentage": 7.6923076923076925,
      "support_ratio": 0.0,
      "abstracts_analyzed": [
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract discusses vascular complications and poorer overall survival in diabetic patients on dialysis, but it does not involve thrombolysis, stroke treatment outcomes after thrombolysis, or any statistical correlation between pre-existing vascular health and post-thrombolysis outcomes. Therefore it neither supports nor contradicts the proposed mechanism, which is specific to post-thrombolysis outcomes.",
          "key_findings": "Diabetic patients with end-stage renal disease have multiple comorbidities including peripheral vascular disease and stroke; they show relatively poor survival rates on dialysis. Factors such as age, left ventricular hypertrophy, hypertension, hypervolemia, anemia, medial arterial calcification, malnutrition, and dialysate composition are associated with increased morbidity and mortality. Death rates on peritoneal dialysis are higher in diabetic than in non-diabetic patients. These findings do not address outcomes after thrombolysis.",
          "pmid": "15467507",
          "title": "Diabetes mellitus and dialysis.",
          "analysis_method": "llm"
        },
        {
          "stance": "conflict",
          "confidence": "high",
          "reasoning": "The proposed mechanism assumes that pre-existing vascular compromise in diabetics (and here, diabetics and/or prior stroke patients) correlates with worse post-thrombolysis outcomes. This trial explicitly reports that a history of prior stroke and diabetes mellitus was not associated with poor 90-day functional outcome or mortality after alteplase, and was not an independent predictor of poor outcome in thrombolysis-treated acute ischemic stroke patients. This directly contradicts the expectation that such pre-existing vascular conditions worsen post-thrombolysis outcomes.",
          "key_findings": "In 3288 AIS patients treated with low- or standard-dose alteplase, a history of prior stroke and diabetes mellitus was not associated with poor 90-day outcome defined by mRS 2\u20136 (OR 0.85, 95% CI 0.55\u20131.32; P=0.476) or mortality (OR 1.25, 95% CI 0.62\u20132.52; P=0.533). History of prior stroke and diabetes was not an independent predictor of poor outcome, and there was no differential effect of alteplase dose on outcomes by history of prior stroke and diabetes.",
          "pmid": "29571842",
          "title": "Comparative effects of low-dose versus standard-dose alteplase in ischemic patients with prior stroke and/or diabetes mellitus: The ENCHANTED trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract examines associations between post-MI creatine kinase levels and bleeding outcomes after thrombolysis, not the impact of pre-existing vascular health in diabetics on post-thrombolysis outcomes. Diabetes is only reported as a baseline characteristic and is not analyzed as a vascular health predictor of outcomes. Thus it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "In 3339 STEMI patients treated with rt-PA, higher peak CK levels were associated with increased odds of fatal/non-fatal bleeding and bleeding/all-cause mortality (adjusted OR 2.6 and 3.1 per log CKmax increase). Diabetes mellitus was present in 13% of patients but not evaluated as a predictor of post-thrombolysis outcomes.",
          "pmid": "32675301",
          "title": "Creatine kinase is associated with bleeding after myocardial infarction.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract shows that diabetes is an independent predictor of worse outcomes after thrombolysis for acute myocardial infarction, but it does not examine or quantify pre-existing vascular health status (e.g., measures of vascular function, atherosclerotic burden beyond triple-vessel disease, microvascular disease) as the mediating mechanism. Worse outcomes are associated with diabetes as a condition, not specifically with objectively assessed poor vascular health in diabetics, so the proposed mechanistic link is not directly tested.",
          "key_findings": "In a cohort of 41,021 thrombolysis-treated MI patients, those with diabetes (n=5,944) were older, more often female, more likely to have anterior MI, delayed thrombolysis, and triple-vessel coronary disease. Diabetic patients had higher 30-day mortality (12.5% in insulin-treated diabetics, 9.7% in non\u2013insulin-treated vs 6.2% in nondiabetics) and higher 1-year mortality (14.5% vs 8.9% in nondiabetics), and more frequent complications (cardiac failure, shock, AV block, atrial fibrillation/flutter). Diabetes remained an independent predictor of mortality, but the study did not specifically analyze poor pre-existing vascular health as a mediator of these worse post-thrombolysis outcomes.",
          "pmid": "9207639",
          "title": "Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract examines admission heart rate and its relationship with angiographic and clinical outcomes in right coronary artery STEMI patients undergoing PCI. It does not analyze pre-existing vascular health, diabetes-specific vascular status, or outcomes after thrombolysis in diabetics. Although diabetes history is mentioned as more frequent in tachycardic patients, the study does not assess whether poor vascular health in diabetics correlates with worse post-thrombolysis outcomes, so it neither supports nor contradicts the proposed mechanism.",
          "key_findings": "In 1460 right coronary artery STEMI patients undergoing primary PCI, admission tachycardia (>100 bpm) was associated with higher 1-year mortality (HR 5.02) and major adverse cardiac events (HR 2.20), while admission bradycardia (<60 bpm) was not associated with increased mortality or MACE. Diabetes mellitus history was more frequent among patients with tachycardia, but no specific analysis was performed on diabetic vascular health or post-thrombolysis outcomes.",
          "pmid": "28724652",
          "title": "Correlation of Admission Heart Rate With Angiographic and Clinical Outcomes in Patients With Right Coronary Artery ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: HORIZONS-AMI (The Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) Trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract shows that QTc interval prolongation predicts future stroke in type 2 diabetics, but it does not involve thrombolysis, post-thrombolysis outcomes, or explicitly characterize QTc as a direct measure of pre-existing vascular health in that context. Therefore, it neither supports nor contradicts the proposed mechanism about poor vascular health in diabetics correlating with worse post-thrombolysis outcomes.",
          "key_findings": "In a cohort of 471 type 2 diabetic patients followed for a median of 57 months, QTc prolongation (\u2265470 ms\u00bd) was an independent predictor of incident stroke with adjusted hazard ratios of 2.2\u20132.9 (95% CI 1.1\u20136.0). Other independent predictors included older age, baseline cerebrovascular disease, higher 24-hour proteinuria, serum triglycerides, left ventricular mass, and lower HDL cholesterol. Excluding patients with prior cerebrovascular disease did not significantly alter these results.",
          "pmid": "12893949",
          "title": "QTc interval prolongation is a predictor of future strokes in patients with type 2 diabetes mellitus.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "medium",
          "reasoning": "The abstract shows that diabetic status is independently associated with poorer myocardial reperfusion and worse 30-day outcomes after primary PCI for STEMI, but it does not assess or adjust for pre-existing vascular health metrics, nor does it analyze whether vascular health specifically mediates or correlates with post-thrombolysis outcomes. The proposed mechanism concerns a statistical correlation between vascular health status within diabetics and outcomes after thrombolysis, which is not directly examined here.",
          "key_findings": "In the ATLANTIC trial sub-analysis, 214 of 1,630 STEMI patients had diabetes mellitus. Diabetes was an independent predictor of poorer myocardial reperfusion (less frequent \u226570% ST-segment resolution after PCI; OR 0.59, 95% CI 0.43\u20130.82) and worse 30-day composite outcomes (death/new MI/urgent revascularization/definite stent thrombosis; OR 2.80, 95% CI 1.62\u20134.85), as well as higher risk of new MI or definite acute stent thrombosis (OR 2.46) and definite stent thrombosis alone (OR 10.00). No significant interaction was observed between timing of ticagrelor administration (pre-hospital vs in-hospital) and diabetes status. Vascular health status per se and its correlation with outcomes are not directly measured or analyzed.",
          "pmid": "30302940",
          "title": "Pre-hospital administration of ticagrelor in diabetic patients with ST-elevation myocardial infarction undergoing primary angioplasty: A sub-analysis of the ATLANTIC trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract compares outcomes of primary PCI vs fibrinolysis in diabetic vs nondiabetic patients with STEMI and shows higher overall 30-day mortality in diabetics. However, it does not analyze or attribute these worse outcomes to pre-existing vascular health, nor does it correlate specific vascular health markers with post-thrombolysis outcomes. The mechanism is about vascular status influencing post-thrombolysis results, whereas this study focuses on treatment modality (PCI vs fibrinolysis) and diabetic status, without mechanistic vascular-health analysis.",
          "key_findings": "Among 6315 STEMI patients, 877 (14%) had diabetes; 30-day mortality was higher in diabetics than nondiabetics (9.4% vs 5.9%). Primary PCI reduced mortality compared with fibrinolysis in both diabetics (OR 0.49, 95% CI 0.31\u20130.79) and nondiabetics (OR 0.69, 95% CI 0.54\u20130.86), with no heterogeneity of treatment effect by diabetes status. Recurrent infarction and stroke were also reduced after primary PCI in both groups. No measures of pre-existing vascular health or specific analysis of post-thrombolysis outcomes in relation to vascular status were reported.",
          "pmid": "17620527",
          "title": "Primary percutaneous coronary intervention compared with fibrinolysis for myocardial infarction in diabetes mellitus: results from the Primary Coronary Angioplasty vs Thrombolysis-2 trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract studies cardiac structural and functional changes in type 1 diabetics, particularly left atrial contribution to left ventricular filling, but it does not involve thrombolysis, stroke, post-thrombolysis outcomes, or correlations between vascular health and thrombolysis outcomes. Thus it neither supports nor contradicts the proposed statistical mechanism.",
          "key_findings": "In type 1 diabetes, relative wall thickness and ejection fraction are increased, indexed end-systolic volume is reduced, and there are alterations in left atrial transport function suggesting greater reliance on atrial contribution to LV filling, while early diastolic LV filling remains normal. No data on thrombolysis or post-thrombolysis outcomes are presented.",
          "pmid": "16762752",
          "title": "Alterations in left ventricular structure and function in type-1 diabetics: a focus on left atrial contribution to function.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract examines relative lymphocyte count as a prognostic marker in patients hospitalized for heart failure and its association with postdischarge outcomes. It does not study diabetics specifically, does not assess pre-existing vascular health, and does not involve post-thrombolysis outcomes. Therefore, it neither supports nor contradicts the proposed mechanism about vascular health in diabetics and thrombolysis outcomes.",
          "key_findings": "Low relative lymphocyte percentage at hospitalization for heart failure is associated with older age, more comorbidities (including diabetes), and markers of more severe HF, and independently predicts higher all-cause mortality and higher risk of cardiovascular death or HF hospitalization within 100 days postdischarge, even after adjustment for multiple clinical risk factors.",
          "pmid": "23051949",
          "title": "Predictive value of low relative lymphocyte count in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "medium",
          "reasoning": "The proposed mechanism concerns poor pre-existing vascular health in diabetics and its correlation with worse outcomes after thrombolysis. This abstract instead studies diabetics undergoing primary PCI (not thrombolysis) for acute myocardial infarction and evaluates myocardial perfusion (MBG, STR), not clinical outcomes per se after thrombolytic therapy. While it shows diabetics have worse microvascular perfusion despite similar epicardial flow, it does not directly link pre-existing vascular health to post-thrombolysis outcomes, nor does it involve thrombolytic treatment.",
          "key_findings": "In patients with AMI undergoing primary PCI, diabetics had higher rates of absent myocardial perfusion (MBG 0/1: 56.0% vs 47.1%, p=0.01) and absent ST-segment resolution (20.3% vs 8.1%, p=0.002) despite similar high rates of TIMI 3 flow. Diabetes mellitus was an independent predictor of absent myocardial perfusion and absent STR on multivariate analysis, and diminished microvascular perfusion may contribute to adverse outcomes.",
          "pmid": "15708696",
          "title": "Impact of diabetes mellitus on myocardial perfusion after primary angioplasty in patients with acute myocardial infarction.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The proposed mechanism concerns how pre-existing vascular health in diabetics correlates with outcomes after thrombolysis. The abstract instead examines renal insufficiency as a predictor of painless myocardial infarction and related in-hospital outcomes, without analyzing diabetic vascular status, thrombolytic therapy, or post-thrombolysis outcomes. Thus it does not directly support or contradict the specified statistical mechanism.",
          "key_findings": "In a retrospective analysis of MI patients, univariate predictors of painless MI included older age, renal insufficiency, and previous MI, but multivariate analysis identified only renal insufficiency as an independent predictor. Patients with painless MI had longer time from symptom onset to admission, higher Killip class (\u2265 II), and higher in-hospital mortality. The study does not evaluate vascular health in diabetics or outcomes after thrombolysis.",
          "pmid": "17721012",
          "title": "Renal insufficiency is related to painless myocardial infarction.",
          "analysis_method": "llm"
        },
        {
          "stance": "neutral",
          "confidence": "high",
          "reasoning": "The abstract examines how degree of ST-segment resolution after primary PCI predicts long-term outcomes in STEMI patients and notes that patients with poor STR are more likely to have diabetes. However, it does not specifically analyze whether pre-existing vascular health in diabetics (or diabetes per se) statistically correlates with worse post-thrombolysis outcomes, nor does it focus on thrombolytic therapy outcomes in diabetics. Thus it neither directly supports nor contradicts the proposed mechanism.",
          "key_findings": "1) Patients with <30% ST-segment resolution at 60 minutes after primary PCI had higher rates of major adverse cardiovascular events, target vessel revascularization, and mortality at 3 years. 2) STR <30% was independently associated with increased risk of 3-year major adverse cardiovascular events (HR 1.58) and ischemia-driven target vessel revascularization (HR 1.87). 3) Patients with STR <30% were more likely to have hypertension and diabetes mellitus, but the study did not isolate or test the specific impact of pre-existing vascular health in diabetics on post-thrombolysis outcomes.",
          "pmid": "23652600",
          "title": "Relationship between ST-segment recovery and clinical outcomes after primary percutaneous coronary intervention: the HORIZONS-AMI ECG substudy report.",
          "analysis_method": "llm"
        }
      ]
    },
    {
      "feature_name": "Previous stroke history",
      "mechanism": {
        "mechanism_type": "biological",
        "description": "Repeated strokes suggest progressive vascular diseases reducing acute response potential.",
        "evidence_level": "strong"
      },
      "query": "(stroke OR alteplase OR thrombolysis OR \"ischemic stroke\") AND \"Previous stroke history\" AND (\"pathophysiology\" OR \"mechanism\" OR \"causal\" OR \"etiology\" OR \"interaction\") AND (\"progressive\" OR \"potential\" OR \"response\") AND (Clinical Trial[PT] OR Review[PT] OR Meta-Analysis[PT])",
      "total_abstracts": 0,
      "support_count": 0,
      "conflict_count": 0,
      "neutral_count": 0,
      "abstracts_analyzed": []
    },
    {
      "feature_name": "Previous stroke history",
      "mechanism": {
        "mechanism_type": "physiological",
        "description": "Persisting deficits from past strokes may lead to diminished plasticity, reducing response to treatment.",
        "evidence_level": "moderate"
      },
      "query": "(stroke OR alteplase OR thrombolysis OR \"ischemic stroke\") AND \"Previous stroke history\" AND (\"physiology\" OR \"pathogenesis\" OR \"homeostasis\") AND (\"persisting\" OR \"diminished\" OR \"plasticity\") AND (Clinical Trial[PT] OR Review[PT] OR Meta-Analysis[PT])",
      "total_abstracts": 0,
      "support_count": 0,
      "conflict_count": 0,
      "neutral_count": 0,
      "abstracts_analyzed": []
    },
    {
      "feature_name": "Previous stroke history",
      "mechanism": {
        "mechanism_type": "pharmacological",
        "description": "Prior stroke-induced vascular changes, such as vessel reactivity alterations, may impair alteplase efficacy, complicating expected pharmacodynamics.",
        "evidence_level": "speculative"
      },
      "query": "(stroke OR alteplase OR thrombolysis OR \"ischemic stroke\") AND \"Previous stroke history\" AND (\"pharmacokinetics\" OR \"pharmacodynamics\" OR \"dose-response\" OR \"clearance\") AND (\"pharmacodynamics\" OR \"complicating\" OR \"alterations\") AND (Clinical Trial[PT] OR Review[PT] OR Meta-Analysis[PT])",
      "total_abstracts": 0,
      "support_count": 0,
      "conflict_count": 0,
      "neutral_count": 0,
      "abstracts_analyzed": []
    }
  ]
}